

---

List of tables .....	2
1 Tradename(s) .....	2
2 Description and composition .....	3
3 Indications.....	3
4 Dosage regimen and administration .....	4
5 Contraindications.....	7
6 Warnings and precautions.....	7
7 Adverse drug reactions .....	14
8 Interactions .....	22
9 Pregnancy, lactation, females and males of reproductive potential.....	26
9.1 Pregnancy .....	26
9.2 Lactation .....	27
9.3 Females and males of reproductive potential .....	27
10 Overdosage .....	28
11 Clinical pharmacology.....	29
12 Clinical studies .....	32
13 Non-clinical safety data.....	32
14 Pharmaceutical information.....	33
15 References .....	35
16 CDS history table .....	54

## List of tables

Table 7-1	Adverse drug reactions .....	14
Table 7-2	Adverse drug reactions from spontaneous reports and literature (frequency not known) .....	

17

## 1 Tradename(s)

TEGRETOL<sup>®</sup> 100 mg, 200 mg and 400 mg tablets

TEGRETOL<sup>®</sup> 200 mg and 400 mg CR tablets (modified-release film-coated tablets)

TEGRETOL<sup>®</sup> 100 mg chewable tablets

TEGRETOL<sup>®</sup> 100 mg / 5 mL oral suspension

TEGRETOL® 125 and 250 mg suppositories

## 2 Description and composition

### Pharmaceutical forms

**Tablets:** 100 mg, 200 mg and 400 mg carbamazepine.

**CR tablets** (modified-release film-coated tablets, divisible): 200 mg and 400 mg carbamazepine.

**Chewable tablets** (scored): 100 mg carbamazepine.

**Oral suspension:** 5 mL (= 1 measure) contain 100 mg carbamazepine.

**Suppositories:** 125 mg and 250 mg carbamazepine.

Information might differ in some countries.

**Active substance** Carbamazepine.

### Excipients

**Tablets:** Silica, colloidal anhydrous, cellulose, microcrystalline, magnesium stearate, carmellose sodium, low substituted.

**CR tablets:** Silica, colloidal anhydrous, ethylcellulose aqueous dispersion, cellulose, microcrystalline, polyacrylate dispersion, magnesium stearate, croscarmellose sodium, talc. Coating: hypromellose, macrogolglycerol hydroxystearate, iron oxide red, iron oxide yellow, talc, titanium dioxide.

**Chewable tablets:** Silica, colloidal anhydrous, aroma cherry mint, erythrosin, gelatine, glycerin pure, magnesium stearate, maize starch, sodium carboxymethyl starch, stearic acid, sucrose (directly compressible).

**Oral suspension:** Cellulose, microcrystalline + sodium CMC, caramel aroma 52929 A, methylparaben, hydroxyethylcellulose, propylene glycol, polyethylene glycol 400 stearate, propylparaben, saccharin sodium, sorbic acid, sorbitol solution, water purified.

**Suppositories:** Hypromellose, Suppository mass 15 (hard fat).

Information might differ in some countries.

## 3 Indications

- Epilepsy [22,24,35,47b,49,56-58,63,149,172]
  - Complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization [287].
  - Generalized tonic-clonic seizures. Mixed forms of seizures.  
Tegretol® is suitable for both monotherapy and combination therapy [24,35,47b,5658,172].

---

Tegretol is usually not effective in absences (petit mal) and myoclonic seizures (see section 6 Warnings and precautions) [35,47b,149,172,208].

- Acute mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence [51,59-61,64,82,156,157].
- Alcohol withdrawal syndrome [47b,98,150].
- Idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis (either typical or atypical). Idiopathic glossopharyngeal neuralgia [21,22,33,179].
- Painful diabetic neuropathy [47b,48].
- Diabetes insipidus centralis [33,47b,48,155]. Polyuria and polydipsia of neurohormonal origin.

## 4 Dosage regimen and administration

### Epilepsy

When possible, Tegretol should be prescribed as monotherapy.

Treatment should be initiated with a low daily dosage, to be slowly increased until an optimal effect is obtained.

The dose of carbamazepine should be adjusted to the needs of the individual patient to achieve adequate control of seizures. Determination of plasma levels may help in establishing the optimum dosage. In the treatment of epilepsy, the dose of carbamazepine usually requires total plasma-carbamazepine concentrations of about 4 to 12 micrograms/mL (17 to 50 micromoles/litre) [311] (see section 6 Warnings and precautions).

When Tegretol is added to existing antiepileptic therapy, this should be done gradually while maintaining or, if necessary, adapting the dosage of the other antiepileptic(s) (see sections 8 Interactions and 11 Clinical pharmacology - Pharmacokinetics).

### General target population / Adults

#### Dosage in Epilepsy

##### Oral forms

Initially, 100 to 200 mg once or twice daily; the dosage should be slowly raised until – generally at 400 mg 2 to 3 times daily – an optimum response is obtained. In some patients 1600 mg or even 2000 mg daily may be appropriate [22,33,44,172].

##### Suppositories

When suppositories are used instead of oral forms the maximum daily dose is limited to 1000 mg (250 mg q.i.d. at 6-hour interval).

No clinical data are available on the use of suppositories in indications other than epilepsy.

**Dosage in Acute mania and maintenance treatment of bipolar affective disorders** Dosage range: about 400 to 1600 mg daily, the usual dosage being 400 to 600 mg daily given in 2 to 3

divided doses. In acute mania, the dosage should be increased rather quickly, whereas small dosage increments are recommended for maintenance therapy of bipolar disorders in order to ensure optimal tolerability [50,72,156,157].

### **Dosage in Alcohol-withdrawal syndrome**

Average dosage: 200 mg 3 times daily. In severe cases, it can be raised during the first few days (e.g. to 400 mg 3 times daily). At the start of treatment for severe withdrawal manifestations, Tegretol should be given in combination with sedative-hypnotic drugs (e.g. clomethiazole, chlordiazepoxide). After the acute stage has abated, Tegretol can be continued as monotherapy.

### **Dosage in Trigeminal neuralgia**

The initial dosage of 200 to 400 mg should be slowly raised daily until freedom from pain is achieved (normally at 200 mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs [311].

### **Dosage in Painful diabetic neuropathy** Average

dosage: 200 mg 2 to 4 times daily.

### **Dosage in Diabetes insipidus centralis**

Average dosage for adults: 200 mg 2 to 3 times daily. In children the dosage should be reduced proportionally to the child's age and body weight.

### **Special populations Renal impairment / Hepatic impairment**

No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.

### **Pediatrics / Children and adolescents**

#### **Dosage in Epilepsy**

##### **Oral forms**

For children aged 4 years or less, a starting dose of 20 to 60 mg/day, increasing by 20 to 60 mg every second day, is recommended. For children over the age of 4 years, therapy may begin with 100 mg/day, increasing at weekly intervals by 100 mg [75,161].

Maintenance dosage: 10 to 20 mg/kg body weight daily in divided doses, e.g.

- Up to 1 year of age: 100 to 200 mg daily (= 5 to 10 mL = 1-2 measures of oral suspension)
- 1 to 5 years of age: 200 to 400 mg daily (= 10 to 20 mL = 2-4 measures of oral suspension)
- 6 to 10 years of age: 400 to 600 mg daily (= 20 to 30 mL = 2-3 measures of oral suspension)

- 11 to 15 years of age: 600 to 1000 mg daily (= 30 to 50 mL = 3  $\square$  2-3 measures of oral suspension (plus an extra measure of 5 mL in case of administration of 1000 mg))  $\square$  >15 years of age: 800 to 1200 mg daily (same as adult dose) [311].

#### **Maximum recommended dose**

Up to 6 years of age: 35 mg/kg/day

6-15 years of age: 1000 mg/day

>15 years of age: 1200 mg/day [311].

#### **Suppositories**

When suppositories are used instead of oral forms, the maximum daily dose is limited to 1000 mg (250 mg q.i.d. at 6-hour intervals).

No clinical data are available on the use of suppositories in indications other than epilepsy.

#### **Dosage in Diabetes insipidus centralis**

In children the dosage should be reduced proportionally to the child's age and body weight. Average dosage for adults: 200 mg 2 to 3 times daily.

#### **Geriatric patients (65 years or above)**

##### **Dosage in Trigeminal neuralgia**

Due to drug interactions and different antiepileptic drug pharmacokinetics, the dosage of Tegretol should be selected with caution in elderly patients [292].

In elderly patients, an initial dose of 100 mg twice daily is recommended. The initial dosage of 100 mg twice daily should be slowly raised daily until freedom from pain is achieved (normally at 200 mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs [311].

#### **Method of administration**

The tablets and the oral suspension (to be shaken before use) may be taken during, after, or between meals. Tablets should be taken with a little liquid [8,9,47b], and possible remnants of the chewable tablets should be washed down with a little liquid.

The CR tablets (either whole or, if so prescribed, only half a tablet) should be swallowed unchewed with a little liquid. The chewable tablets and the oral suspension (one measure = 5 mL = 100 mg; half a measure = 2.5 mL = 50 mg) are particularly suitable for patients who have difficulty in swallowing tablets or need initial careful adjustment of the dosage.

As a result of slow, controlled release of the active substance from the CR tablets, these are designed to be taken in a twice-daily dosage regimen.

Since a given dose of Tegretol oral suspension will produce higher peak levels than the same dose in tablet form, it is advisable to start with low doses and increase them slowly so as to avoid adverse reactions.

Switching patients from Tegretol tablets to oral suspension: this should be done by giving the same number of mg per day in smaller, more frequent doses (e.g. oral suspension three times a day (t.i.d.) instead of tablets twice a day (b.i.d)).

Switching patients from conventional tablets to CR tablets: clinical experience shows that in some patients the dosage in the form of CR tablets may need to be increased [163,165,171,175].

Switching patients from oral formulations to suppositories: the dosage in the form of suppositories needs to be increased by about 25% and given in divided doses, up to a maximum of 250 mg four times a day (q.i.d.) at 6-hour intervals [203-205]. Experience in administration of suppositories is limited to 7 days as replacement therapy in patients in whom oral treatment of epilepsy is temporarily not possible, for example in postoperative or unconscious subjects.

## 5 Contraindications

- Known hypersensitivity to carbamazepine or structurally related drugs (e.g. tricyclic antidepressants) [49,72] or any other component of the formulation
- Patients with atrioventricular block [72]
- Patients with a history of bone-marrow depression [68]
- Patients with a history of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda) [67,70,71,79,90,295]
- The use of Tegretol is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs) [33,50,69,83,295] (see section 8 Interactions).

## 6 Warnings and precautions

Tegretol should be given only under medical supervision [49,65,72]. Tegretol should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic, or renal damage, adverse hematological reactions to other drugs, or interrupted courses of therapy with Tegretol [22,33,67,87].

### Hematological effects

Agranulocytosis and aplastic anemia have been associated with Tegretol; however, due to the very low incidence of these conditions, meaningful risk estimates for Tegretol are difficult to obtain. The overall risk in the general untreated population has been estimated at 4.7 persons per million per year for agranulocytosis and 2.0 persons per million per year for aplastic anemia [206].

Transient or persistent decreased platelet or white blood cell counts occur occasionally to frequently in association with the use of Tegretol. However, in the majority of cases these effects prove transient and are unlikely to signal the onset of either aplastic anemia or agranulocytosis [23,24,47b,50,90]. Nonetheless, complete pretreatment blood counts,

including platelets (and possibly reticulocytes and serum iron), should be obtained at baseline, and periodically thereafter [23,47b,50,65,66,72,73,75,76,90,118,159,160].

If the white blood cell or platelet count is definitely low or decreased during treatment, the patient and the complete blood count should be closely monitored. Tegretol should be discontinued if any evidence of significant bone-marrow depression appears [72,23,68,89,90].

Patients should be made aware of early toxic signs and symptoms of a potential hematological problem, as well as symptoms of dermatological or hepatic reactions. If reactions such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric hemorrhage appear, the patient should be advised to consult the physician immediately [49,90].

### **Serious dermatologic reactions**

Serious dermatologic reactions, including toxic epidermal necrolysis (TEN; also known as Lyell's syndrome) and Stevens-Johnson syndrome (SJS), have been reported very rarely with Tegretol. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal. Most of the SJS/TEN cases appear in the first few months of treatment with Tegretol. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations. If signs and symptoms suggestive of severe skin reactions (e.g. SJS, Lyell's syndrome/TEN) appear, Tegretol should be withdrawn at once and alternative therapy should be considered [24,25,49,65,300,312].

### **Pharmacogenomics**

There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions.

#### **Association with HLA-B\*1502**

Retrospective studies in patients of Han Chinese and Thai origin found a strong correlation between SJS/TEN skin reactions associated with carbamazepine and the presence in these patients of the Human Leukocyte Antigen (HLA)-B\*1502 allele. The frequency of HLAB\*1502 allele ranges from 2 to 12% in Han Chinese populations and is about 8% in Thai populations. Higher reporting rates of SJS (rare rather than very rare) are reported in some countries in Asia (e.g. Taiwan, Malaysia and the Philippines) in which there is a higher frequency of the HLA-B\*1502 allele in the population (e.g. above 15% in the Philippines and some Malaysian populations). Allele frequencies up to about 2% and 6% have been reported in Korea and India, respectively. The frequency of the HLA-B\*1502 allele is negligible in persons of European descent, several African populations, indigenous peoples of the Americas, Hispanic populations sampled and in Japanese (< 1%) [300,312].

The allele frequencies listed here represent the percentage of chromosomes in the specified population that carry the allele of interest, meaning that the percentage of patients who carry a copy of the allele on at least one of their two chromosomes (i.e. the "carrier frequency") is nearly twice as high as the allele frequency. Therefore, the percentage of patients who may be at risk is nearly twice the allele frequency [312].

Testing for the presence of HLA-B\*1502 allele should be considered in patients with ancestry in genetically at-risk populations, prior to initiating treatment with Tegretol (see below Information for the healthcare professionals). The use of Tegretol should be avoided in tested patients who are found to be positive for HLA-B\*1502 unless the benefits clearly outweigh the risks. HLA-B\*1502 may be a risk factor for the development of SJS/TEN in Chinese patients taking other antiepileptic drugs (AED) associated with SJS/TEN. Consideration should therefore be given to avoiding use of other drugs associated with SJS/TEN in HLA-B\*1502 positive patients, when alternative therapies are otherwise equally acceptable. Screening is not generally recommended in patients from populations in which the prevalence of HLA-B\*1502 is low. Screening is generally not recommended for any current Tegretol users, as the risk of SJS/TEN is largely confined to the first few months of therapy, regardless of HLA-B\*1502 status [300].

The identification of subjects carrying the HLA-B\*1502 allele and the avoidance of carbamazepine therapy in these subjects has been shown to decrease the incidence of carbamazepine-induced SJS/TEN [309].

#### **Association with HLA-A\*3101**

Human Leukocyte Antigen (HLA)-A\*3101 may be a risk factor for the development of cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash. Retrospective genome-wide studies in Japanese and Northern European populations reported association between severe skin reactions (SJS, TEN, DRESS, AGEP and maculopapular rash) associated with carbamazepine use and the presence of the HLA-A\*3101 allele in these patients.

The frequency of the HLA-A\*3101 allele varies widely between ethnic populations and its frequency is about 2 to 5% in European populations and about 10% in the Japanese population [312]. The frequency of this allele is estimated to be less than 5% in the majority of Australian, Asian, African and North American populations, with some exceptions within 5-12%. Prevalence above 15% has been estimated in some ethnic groups in South America (Argentina and Brazil), North America (US Navajo and Sioux, and Mexico Sonora Seri) and Southern India (Tamil Nadu) and between 10%-15% in other native ethnicities in these same regions.

The allele frequencies listed here represent the percentage of chromosomes in the specified population that carry the allele of interest, meaning that the percentage of patients who carry a copy of the allele on at least one of their two chromosomes (i.e. the “carrier frequency”) is nearly twice as high as the allele frequency. Therefore, the percentage of patients who may be at risk is nearly twice the allele frequency [312].

Testing for the presence of HLA-A\*3101 allele should be considered in patients with ancestry in genetically at-risk populations (for example, patients of the Japanese and Caucasian populations, patients who belong to the indigenous populations of the Americas, Hispanic populations, people of southern India, and people of Arabic descent), prior to initiating treatment with Tegretol (see below Information for the healthcare professionals). The use of Tegretol should be avoided in patients who are found to be positive for HLA-A\*3101, unless the benefits clearly outweigh the risks. Screening is generally not recommended for any current Tegretol users, as the risk of SJS/TEN, AGEP, DRESS and maculopapular rash is largely confined to the first few months of therapy, regardless of HLA-A\*3101 status [309].

### **Limitation of genetic screening**

Genetic screening results must never substitute for appropriate clinical vigilance and patient management. Many Asian patients positive for HLA-B\*1502 and treated with Tegretol will not develop SJS/TEN and patients negative for HLA-B\*1502 of any ethnicity can still develop SJS/TEN. Similarly many patients positive for HLA-A\*3101 and treated with Tegretol will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A\*3101 of any ethnicity can still develop these severe cutaneous adverse reactions. The role of other possible factors in the development of, and morbidity from, these severe cutaneous adverse reactions, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied [300,309].

### **Information for the healthcare professionals**

If testing for the presence of the HLA-B\*1502 allele is performed, high-resolution “HLA-B\*1502 genotyping” is recommended. The test is positive if either one or two HLA-B\*1502 alleles are detected and negative if no HLA-B\*1502 alleles are detected [300]. Similarly if testing for the presence of the HLA-A\*3101 allele is performed, high-resolution “HLA-A\*3101 genotyping” respectively is recommended. The test is positive if either one or two HLA-A\*3101 alleles are detected and negative if no HLA-A\*3101 alleles are detected [309].

### **Other dermatologic reactions**

Mild skin reactions, e.g. isolated macular or maculopapular exanthema, can also occur and are mostly transient and not hazardous. They usually disappear within a few days or weeks, either during the continued course of treatment or following a decrease in dosage. However, since it may be difficult to differentiate the early signs of more serious skin reactions from mild transient reactions, the patient should be kept under close surveillance with consideration given to immediately withdrawing the drug should the reaction worsen with continued use [25,50,65,138,300].

The HLA-A\*3101 allele has been found to be associated with less severe adverse cutaneous reactions from carbamazepine and may predict the risk of these reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption). However, the HLA-B\*1502 allele has not been found to predict the risk of these aforementioned skin reactions [300,309].

## Hypersensitivity

Tegretol may trigger hypersensitivity reactions, including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), a delayed multi-organ hypersensitivity disorder with fever, rash, vasculitis, lymphadenopathy, pseudolymphoma, arthralgia, leukopenia, eosinophilia, hepatosplenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), [307] that may occur in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium, colon). See section 7 Adverse drug reactions [295,312].

The HLA-A\*3101 allele has been found to be associated with the occurrence of hypersensitivity syndrome, including maculopapular rash [309].

Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that approximately 25 to 30% of these patients may experience hypersensitivity reactions with oxcarbazepine (Trileptal<sup>®</sup>) [293].

Cross-hypersensitivity can occur between carbamazepine and aromatic antiepileptic drugs (e.g. phenytoin, primidone and phenobarbital) [293, 315].

In general, if signs and symptoms suggestive of hypersensitivity reactions occur, Tegretol should be withdrawn immediately [295].

## Seizures

Tegretol should be used with caution in patients with mixed seizures, which includes absences, either typical or atypical. In all these conditions, Tegretol may exacerbate seizures. In the event of exacerbation of seizures, Tegretol should be discontinued [24,81,87,88,178].

An increase in seizure frequency may occur during the switch from an oral formulation to suppositories.

## Hepatic function

Baseline and periodic evaluations of hepatic function must be performed during treatment with Tegretol, particularly in patients with a history of liver disease and in elderly patients. The drug should be withdrawn immediately in cases of aggravated liver dysfunction or active liver disease [47b,49,91].

## Renal function

Baseline and periodic complete urinalysis and BUN determinations are recommended [49].

## Hyponatremia

Hyponatremia is known to occur with carbamazepine. In patients with pre-existing renal conditions associated with low sodium or in patients treated concomitantly with sodiumlowering medicinal products (e.g. diuretics, medicinal products associated with inappropriate ADH secretion), serum sodium levels should be measured prior to initiating carbamazepine therapy. Thereafter, serum sodium levels should be measured after

approximately two weeks and then at monthly intervals for the first three months during therapy, or according to clinical need. These risk factors may apply especially to elderly patients. If hyponatremia is observed, water restriction is an important counter-measurement if clinically indicated [312].

### **Hypothyroidism**

Carbamazepine may reduce serum concentrations of thyroid hormones through enzyme induction requiring an increase in dose of thyroid replacement therapy in patients with hypothyroidism. Hence thyroid function monitoring is suggested to adjust the dosage of thyroid replacement therapy [312].

### **Anticholinergic effects**

Tegretol has shown mild anticholinergic activity. Patients with increased intraocular pressure and urinary retention should therefore be closely observed during therapy (see section 7 Adverse drug reactions) [33,80,312].

### **Psychiatric effects**

The possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind [35,49,65].

### **Suicidal ideation and behaviour**

Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomized placebo-controlled trials of antiepileptic drugs has shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known.

Therefore patients should be monitored for signs of suicidal ideation and behaviour and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge [305].

### **Pregnancy and females of reproductive potential**

Carbamazepine may be associated with fetal harm when administered to a pregnant woman (see section 9 Pregnancy, lactation, females and males of reproductive potential). Tegretol should be used during pregnancy only if the potential benefit justifies the potential risks.

Adequate counselling should be made available to all pregnant women and women of childbearing potential, regarding the risks associated with pregnancy due to potential teratogenic risk to the fetus (see section 9 Pregnancy, lactation, females and males of reproductive potential).

Women of childbearing potential should use effective contraception during treatment with carbamazepine and for 2 weeks after the last dose (see below sub-sections “Endocrinological effects” and “Interactions”) (see section 9 Pregnancy, lactation, females and males of reproductive potential) [317].

### **Endocrinological effects**

Breakthrough bleeding has been reported in women taking Tegretol while using hormonal contraceptives. The reliability of hormonal contraceptives may be adversely affected by Tegretol [33,49,69,72] and women of child-bearing potential should be advised to consider using alternative forms of birth control while taking Tegretol.

### **Monitoring of plasma levels**

Although correlations between dosage and plasma levels of carbamazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma levels may be useful in the following situations: dramatic increase in seizure frequency/verification of patient compliance; during pregnancy; when treating children or adolescents; in suspected absorption disorders; in suspected toxicity when more than one drug is being used (see section 8 Interactions) [1,21,44,49,50,77].

### **Dose reduction and withdrawal effects**

Abrupt withdrawal of Tegretol may precipitate seizures, therefore carbamazepine should be withdrawn gradually over a 6-month period. If treatment with Tegretol has to be withdrawn abruptly in a patient with epilepsy, the switch to the new antiepileptic compound should be made under cover of a suitable drug [312].

### **Interactions**

Co-administration of inhibitors of CYP3A4 or inhibitors of epoxide hydrolase with carbamazepine can induce adverse reactions (increase of carbamazepine or carbamazepine<sub>10,11</sub> epoxide plasma concentrations, respectively). The dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored.

Co-administration of CYP3A4 inducers with carbamazepine may decrease carbamazepine plasma concentrations and its therapeutic effect, while discontinuation of a CYP3A4 inducer may increase carbamazepine plasma concentrations. The dosage of Tegretol may have to be adjusted.

Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism. See section 8 Interactions.

Female patients of child-bearing potential should be warned that the concurrent use of Tegretol with hormonal contraceptives may render this type of contraceptive ineffective (see sections 8 Interactions and 9 Pregnancy, lactation, females and males of reproductive potential). Alternative non-hormonal forms of contraception are recommended when using Tegretol [312].

### **Driving and using machines**

The patient's ability to react may be impaired by the medical condition, resulting in seizures, and adverse reactions including dizziness, drowsiness ataxia, diplopia, impaired accommodation and blurred vision have been reported with Tegretol, especially at the start of

treatment or in connection with dose adjustments. Patients should therefore exercise due caution when driving a vehicle or operating machinery [68,312].

## Falls

Tegretol treatment has been associated with ataxia, dizziness, somnolence, hypotension, confusional state, sedation (see section 7 Adverse drug reactions) which may lead to falls and, consequently fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete risk assessment of fall should be considered recurrently for patients on long-term Tegretol treatment [315].

## Special excipients

Tegretol oral suspension contains parahydroxybenzoates which may cause allergic reactions (possibly delayed). It also contains sorbitol and therefore should not be administered to patients with rare hereditary problems of fructose intolerance.

## 7 Adverse drug reactions

### Summary of the safety profile

Particularly at the start of treatment with Tegretol, or if the initial dosage is too high, or when treating elderly patients, certain types of adverse reaction occur very commonly or commonly, e.g. CNS adverse reactions (dizziness, headache, ataxia, drowsiness, fatigue, diplopia), gastrointestinal disturbances (nausea, vomiting), and allergic skin reactions [33,48,49,50,65,72,149,178].

The dose-related adverse reactions usually abate within a few days, either spontaneously or after a transient dosage reduction. The occurrence of CNS adverse reactions may be a manifestation of relative overdosage or significant fluctuation in plasma levels. In such cases it is advisable to monitor plasma levels [50,72].

### Tabulated summary of adverse drug reactions compiled from clinical trials and from spontaneous reports

Adverse drug reactions from clinical trials (Table 7-1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ).

**Table 7-1 Adverse drug reactions**

<b>Blood and lymphatic system disorders</b>	Very common: leukopenia.
---	--------------------------

Common: thrombocytopenia, eosinophilia.

Rare: leukocytosis, lymphadenopathy [23-25,50,65,90,178].

Very rare: agranulocytosis, aplastic anaemia, pancytopenia [295],  
aplasia pure red cell, anaemia [295,312], anaemia megaloblastic,  
reticulocytosis, haemolytic anaemia [23,24,50,65,67,80,90,162,312].

**Immune system disorders**

Rare: a delayed multiorgan hypersensitivity disorder with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leukopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the

	intrahepatic bile ducts), occurring in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium, colon) [22,49,67,80,86,135,164,178,222,223,307,312].
[224,312],	Very rare: anaphylactic reaction [80], angioedema
<b>Endocrine disorders</b>	hypogammaglobulinaemia [298,312].
	Common: oedema, fluid retention, weight increase, hyponatraemia and blood osmolality decreased due to an antidiuretic hormone (ADH)-like effect leading in rare cases to water intoxication accompanied by lethargy, vomiting, headache, confusional state, neurological disorders [22,23,49,50,67,178].
	Very rare: galactorrhoea, gynaecomastia [80,312].
<b>Metabolism and nutrition disorders</b>	
	Rare: folate deficiency, decreased appetite [312].
	Very rare: porphyria acute (acute intermittent porphyria and variegate porphyria), porphyria non-acute (porphyria cutanea tarda) [295,312].
<b>Psychiatric disorders</b>	
	Rare: hallucinations (visual or auditory), depression, aggression, agitation, restlessness, confusional state.
	Very rare: activation of psychosis [48-50].
<b>Nervous system disorders</b>	
	Very common: ataxia, dizziness, somnolence [312].
	Common: diplopia, headache, [48,50,65,72].
	Uncommon: abnormal involuntary movements (e.g. tremor, asterixis, dystonia, tics) [80,178], nystagmus [48,50,67].
	Rare: dyskinesia [312], eye movement disorder [312], speech disorders (e.g. dysarthria, slurred speech), choreoathetosis, neuropathy peripheral, paraesthesia, paresis [49,50,67,80].
	Very rare: neuroleptic malignant syndrome [218-220,295], aseptic meningitis with myoclonus and peripheral eosinophilia [184,185,312], dysgeusia [25,65,312].
<b>Eye disorders</b>	
	Common accommodation disorders (e.g. blurred vision) [312] Very rare: lenticular opacities [80], conjunctivitis [80].
<b>Ear and labyrinth disorders</b>	
	Very rare: hearing disorders, e.g. tinnitus [49,80,181], hyperacusis [80], hypoacusis [225], change in pitch perception [226,227].
<b>Cardiac disorders</b>	
	Rare: cardiac conduction disorders [49,50,67,80].
	Very rare: arrhythmia, atrioventricular block with syncope, bradycardia, cardiac failure congestive, coronary artery disease aggravated, [22,33,35,49,50,67,68,80,84,295,312].
<b>Vascular disorders</b>	
	Rare: hypertension or hypotension [312]

embolism), Very Rare: circulatory collapse, embolism (e.g. pulmonary thrombophlebitis [\[22,33,35,49,50,67,68,80,84,295,312\]](#)).



### **Respiratory, thoracic and mediastinal disorders**

Very rare: pulmonary hypersensitivity characterized e.g. by fever, dyspnoea, pneumonitis or pneumonia [48,67,80,85].

### **Gastrointestinal disorders**

Very common: vomiting, nausea [48-50,72].  
Common: dry mouth [33,49,68]; with suppositories, rectal irritation may occur [203,205].

Uncommon: diarrhoea, constipation [33,48,49,72].  
Rare: abdominal pain.

Very rare: pancreatitis [135,221], glossitis, stomatitis [33,48,49,68].

### **Hepatobiliary disorders**

Rare: hepatitis of cholestatic, parenchymal (hepatocellular) or mixed type, vanishing bile duct syndrome [307], jaundice.

Very rare: hepatic failure [293], granulomatous liver disease [33,49,65,67,312].

### **Skin and subcutaneous tissue disorders**

Very common: urticaria which may be severe, dermatitis allergic [24,33,48-50,65].

Uncommon: dermatitis exfoliative [312].

Rare: systemic lupus erythematosus [25,48,50,80,90], pruritus.

Very rare: Stevens-Johnson syndrome\* [288-291], toxic epidermal necrolysis, photosensitivity reaction, erythema multiforme, erythema nodosum, pigmentation disorder [312], purpura, acne, hyperhidrosis, alopecia [25,33,48-50,67,80,90,312], hirsutism [190,191,302].

### **Musculoskeletal, connective tissue and bone disorders**

Rare muscular weakness

Very rare: bone metabolism disorders (decrease in plasma calcium and blood 25hydroxy-cholecalciferol) leading to osteomalacia/osteoporosis [50,67,80,149,295,312], arthralgia, myalgia, muscle spasms [49,80,312].

### **Renal and urinary disorders**

Very rare: tubulointerstitial nephritis [312], renal failure, renal impairment (e.g. albuminuria, haematuria, oliguria, and blood urea increased/azotemia), urinary retention, urinary frequency.

### **Reproductive system**

Very rare: sexual dysfunction/erectile dysfunction, spermatogenesis abnormal (with decreased sperm count and/or motility) [23,33,48,49,80,295,312].

### **General disorders and administration site conditions**

Very common fatigue [312].

### **Investigations**

Very common: gamma-glutamyltransferase increased (due to hepatic enzyme induction), usually not clinically relevant [24,72,312].

Common: blood alkaline phosphatase increased [312].

Uncommon: transaminases increased

[23,33,50,65,72,81,90,312].

Very rare: intraocular pressure increased [295,312], blood cholesterol increased, high density lipoprotein increased, blood triglycerides increased [80,9294,312]. Thyroid function test abnormal: decreased L-Thyroxin (free thyroxine, thyroxine, tri-iodothyronine) and increased blood thyroid stimulating hormone, usually without clinical manifestations [23,50,65,80,312], blood prolactin increased [80,312],

\* In some Asian countries also reported as rare. See also section 6 Warnings and precautions.

### **Additional adverse drug reactions from spontaneous reports (frequency not known)**

The following adverse drug reactions have been derived from post-marketing experience with Tegretol via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

**Table 7-2 Adverse drug reactions from spontaneous reports and literature (frequency not known)**

---

#### **Infections and infestations**

Reactivation of Human herpes virus 6 infection [312].

**Blood and lymphatic system disorders** Bone marrow failure [312].

#### **Injury, poisoning and procedural complications**

Fall (associated with Tegretol treatment induced ataxia, dizziness, somnolence, hypotension, confusional state, sedation) [315] (see section 6 Warning and precautions).

#### **Nervous system disorders**

Sedation, memory impairment [312].

#### **Gastrointestinal disorders**

Colitis [312].

#### **Immune system disorders**

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) [308].

#### **Skin and subcutaneous tissue disorders**

Acute Generalized Exanthematous Pustulosis (AGEP) [308], lichenoid keratosis, onychomadesis [312].

**Musculoskeletal and connective tissue disorders** Fracture [312].

#### **Investigations**

Bone density decreased [312].

---

## 8 Interactions

Cytochrome P450 3A4 (CYP3A4) is the main enzyme catalyzing formation of the active metabolite carbamazepine-10,11-epoxide. Co-administration of inhibitors of CYP3A4 may result in increased carbamazepine plasma concentrations which could induce adverse reactions [294]. Co-administration of CYP3A4 inducers might increase the rate of carbamazepine metabolism, thus leading to potential decreases in the carbamazepine serum level and therapeutic effect [214,294]. Similarly, discontinuation of a CYP3A4 inducer may decrease the rate of metabolism of carbamazepine, leading to an increase in carbamazepine plasma levels [293].

Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism [294].

Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide [301]. Co-administration of inhibitors of human microsomal epoxide hydrolase may result in increased carbamazepine-10,11 epoxide plasma concentrations [301].

### Interactions resulting in a contraindication

The use of Tegretol is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs); before administering Tegretol MAOIs should be discontinued for a minimum of 2 weeks, or longer if the clinical situation permits (see section 5 Contraindications) [33,50,69,83,295].

### Agents that may raise carbamazepine plasma levels

**Since raised plasma carbamazepine levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:**

Analgesics, anti-inflammatory drugs: dextropropoxyphene, ibuprofen [295].

Androgens: danazol [125,126].

Antibiotics: macrolide antibiotics (e.g. erythromycin, troleandomycin [119,120], josamycin [121], clarithromycin [246-248]), ciprofloxacin [310].

Antidepressants: possibly desipramine [128], fluoxetine [186,187], fluvoxamine [234-241], nefazodone [242-245], paroxetine [297], trazodone [294,295], viloxazine [303,304].

Antiepileptics: stiripentol [294,295], vigabatrin [294,295].

Antifungals: azoles [214,249,250] (e.g. itraconazole, ketoconazole, fluconazole, voriconazole [294,295]). Alternative anticonvulsants may be recommended in patients treated with voriconazole or itraconazole [313].

Antihistamines: loratadine, terfenadine [251].

Antipsychotics: olanzapine [295].

Antituberculosis: isoniazid.

Antivirals: protease inhibitors for HIV treatment (e.g. ritonavir) [293].

Carbonic anhydrase inhibitors: acetazolamide [26,27,123,124].

Cardiovascular drugs: diltiazem, verapamil.

Gastrointestinal drugs: possibly cimetidine, omeprazole [294,295].

Muscle relaxants: oxybutynin [294,295], dantrolene [294,295].

Platelet aggregation inhibitors: ticlopidine [294,295].

Other interactions: grapefruit juice, nicotinamide (only in high dosage) [129,130,313].

### **Agents that may raise the active metabolite carbamazepine-10,11-epoxide plasma levels**

Since raised plasma carbamazepine-10,11-epoxide levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:

Loxapine [294,301], quetiapine [294,301], primidone, progabide [69,146,301], valproic acid, valnoctamide and valpromide [69,101,102,301].

### **Agents that may decrease carbamazepine plasma levels**

The dose of Tegretol may have to be adjusted when used concomitantly with the substances described below:

Antiepileptics: felbamate [258-262], methsuximide [252,253], oxcarbazepine, phenobarbital [69,137,138], phensuximide [254], phenytoin (to avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms/mL before adding carbamazepine to the treatment [313]) and fosphenytoin [100,136,137,294], primidone [137,69,82], and, although the data are partly contradictory, possibly also clonazepam [99,69,139].

Antineoplastics: cisplatin or doxorubicin [256,257].

Antituberculosis: rifampicin [255].

Bronchodilators or anti-asthma drugs: theophylline, aminophylline [69,112,294].

Dermatological drugs: isotretinoin [100,144].

Other interactions: herbal preparations containing St John's wort (*Hypericum perforatum*) [293].

## Effect of Tegretol on plasma levels of concomitant agents

**Carbamazepine may lower the plasma level, or diminish - or even abolish - the activity of certain drugs [1,69,123,134]. The dosage of the following drugs may have to be adjusted to clinical requirements:**

Analgesics, anti-inflammatory agents: buprenorphine [306], methadone [69,110], paracetamol (long-term administration of carbamazepine and paracetamol (acetaminophen) may be associated with hepatotoxicity) [283-286,313], phenazone (antipyrene) [294], tramadol.

Antibiotics: doxycycline [106], rifabutin [313].

Anticoagulants: oral anticoagulants (e.g. warfarin, phenprocoumon, dicoumarol [69,82,114,115,134], acenocoumarol [294,295], rivaroxaban, dabigatran, apixaban, edoxaban [316]).

Antidepressants: bupropion [294,295], citalopram [294,295], mianserin [306], nefazodone [301], sertraline [306], trazodone [294], tricyclic antidepressants (e.g. imipramine [127], amitriptyline, nortriptyline, clomipramine) [273-279].

Antiemetics: aprepitant [310]

Antiepileptics: clobazam [97,98,149], clonazepam [99,149], ethosuximide [103,104,149], felbamate [256-262], lamotrigine [263,264], eslicarbazepine [315], oxcarbazepine, primidone, tiagabine [269,270], topiramate [271,272], valproic acid [100,69,101], zonisamide [265-268]. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms /mL before adding carbamazepine to the treatment [313]. There have been rare reports of an increase in plasma mephenytoin levels [118].

Antifungals: itraconazole, voriconazole. Alternative anticonvulsants may be recommended in patients treated with voriconazole or itraconazole [313].

Anthelmintics: praziquantel, albendazole [310].

Antineoplastics: imatinib [294,295], cyclophosphamide [308], lapatinib [308], temsirolimus [310].

Antipsychotics: clozapine [280-282], haloperidol [107-109] and bromperidol [294], olanzapine [293], quetiapine [294,295], risperidone, ziprasidone [293], aripiprazole [308], paliperidone [310].

Antivirals: protease inhibitors for HIV treatment (e.g. indinavir, ritonavir, saquinavir).

Anxiolytics: alprazolam [145], midazolam.

Bronchodilators or anti-asthma drugs: theophylline [69,113].

Contraceptives: hormonal contraceptives (alternative contraceptive methods should be considered) [69,72,111].

Cardiovascular drugs: calcium channel blockers (dihydropyridine group) e.g. felodipine [122], digoxin [105], simvastatin, atorvastatin, lovastatin, cerivastatin [312,313], ivabradine [313].

Corticosteroids: corticosteroids (e.g. prednisolone, dexamethasone) [134,141,142].

Drugs used in erectile dysfunction: tadalafil [310].

Immunosuppressants: ciclosporin [95,96], everolimus [294,295], tacrolimus [308], sirolimus [310].

Thyroid agents: levothyroxine.

Other drug interactions: products containing oestrogens and/or progesterones.

### **Combinations that require specific consideration**

Concomitant use of carbamazepine and levetiracetam has been reported to increase carbamazepine-induced toxicity [297].

Concomitant use of carbamazepine and isoniazid has been reported to increase isoniazid-induced hepatotoxicity [69,147,148].

Combined use of carbamazepine and lithium [132,133,149] or metoclopramide [131] on the one hand, and carbamazepine and neuroleptics (haloperidol, thioridazine) [107,108] on the other, may lead to increased neurological adverse reactions (with the latter combination even in the presence of 'therapeutic plasma levels').

Concomitant medication with Tegretol and some diuretics (hydrochlorothiazide, furosemide) may lead to symptomatic hyponatremia [140].

Carbamazepine may antagonize the effects of non-depolarizing muscle relaxants (e.g. pancuronium). Their dosage may need to be raised, and patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected [100,143].

Carbamazepine, like other psychoactive drugs, may reduce alcohol tolerance. It is therefore advisable for the patient to abstain from alcohol [69].

Concomitant use of carbamazepine with direct acting oral anti-coagulants (rivaroxaban, dabigatran, apixaban, and edoxaban) may lead to reduced plasma concentrations of direct acting oral anti-coagulants, which carries the risk of thrombosis. Therefore, if a concomitant use is necessary, close monitoring of signs and symptoms of thrombosis is recommended [316].

### **Interference with serological testing**

Carbamazepine may result in false positive perphenazine concentrations in HPLC analysis due to interference.

Carbamazepine and the 10,11-epoxide metabolite may result in false positive tricyclic antidepressant concentration in fluorescence polarized immunoassay method [313].

## 9 Pregnancy, lactation, females and males of reproductive potential

### 9.1 Pregnancy

#### Risk summary

Offspring of epileptic mothers are known to be more prone to developmental disorders, including malformations. Although conclusive evidence from controlled studies with carbamazepine monotherapy is lacking, developmental disorders and malformations, including spina bifida [24,30,31,35-38,41,180-183,193,194] and also other congenital anomalies, e.g. craniofacial defects, cardiovascular malformations, hypospadias and anomalies involving various body systems, have been reported in association with the use of Tegretol [293,295]. Based on data in a North American pregnancy registry, the rate of major congenital malformations, defined as a structural abnormality with surgical, medical, or cosmetic importance, diagnosed within 12 weeks of birth was 3.0% (95% CI 2.1 to 4.2%) among mothers exposed to carbamazepine monotherapy in the first trimester and 1.1% (95% CI 0.35 to 2.5%) among pregnant women not taking any antiepileptic drug (relative risk 2.7, 95% CI 1.1 to 7.0) [312].

#### Clinical considerations

Taking these data into consideration:

- Pregnant women with epilepsy should be treated with special care [30,31,37,112,195,196].
- If women receiving Tegretol become pregnant or plan to become pregnant, or if the need of initiating treatment with Tegretol arises during pregnancy, the drug's expected benefits must be carefully weighed against its possible hazards, particularly in the first 3 months of pregnancy.
- In women of child-bearing potential Tegretol should, wherever possible, be prescribed as monotherapy [30,31], because the incidence of congenital abnormalities in the offspring of women treated with a combination of antiepileptic drugs is greater than in those of mothers receiving the individual drugs as monotherapy [30-32,36]. The risk of malformations following exposure to carbamazepine as polytherapy may vary depending on the specific drugs used and may be higher in polytherapy combinations that include valproate [312].
- Minimum effective doses should be given and monitoring of plasma levels is recommended [30,31,33]. The plasma concentration could be maintained in the lower side of the therapeutic range 4 to 12 micrograms/mL provided seizure control is maintained. There is evidence to suggest that the risk of malformation with carbamazepine may be dosedependent, i.e. at a dose < 400 mg per day, the rates of malformation were lower than with higher doses of carbamazepine [312].
- Patients should be counseled regarding the possibility of an increased risk of malformations and given the opportunity of antenatal screening [207].

- During pregnancy, an effective antiepileptic treatment should not be interrupted, since the aggravation of the illness is detrimental to both the mother and the fetus [296].

### **Monitoring and prevention**

Folic acid deficiency is known to occur in pregnancy. Antiepileptic drugs have been reported to aggravate folic acid deficiency. This deficiency may contribute to the increased incidence of birth defects in the offspring of treated epileptic women. Folic acid supplementation has therefore been recommended before and during pregnancy [31,34,188,189,192,194].

### **In the neonate**

In order to prevent bleeding disorders in the offspring, it has also been recommended that vitamin K1 be given to the mother during the last weeks of pregnancy as well as to the neonate [24,30,31,159].

There have been a few cases of neonatal seizures and/or respiratory depression associated with maternal Tegretol and other concomitant anticonvulsant drug use. A few cases of neonatal vomiting, diarrhea and/or decreased feeding have also been reported in association with maternal Tegretol use. These reactions may represent a neonatal withdrawal syndrome [228].

### **Animal data**

The cumulative evidence from various animal studies in mice, rats and rabbits indicates that carbamazepine has no or only minor teratogenic potential at doses relevant to man. However, the animal studies were insufficient to rule out a teratogenic effect of carbamazepine. In a reproduction study in rats, nursing offspring demonstrated a reduced weight gain at a maternal dosage level of 192 mg/kg/day [314].

## **9.2 Lactation**

### **Risk summary**

Carbamazepine passes into the breast milk (about 25 to 60% of plasma concentrations) [42-44]. The benefits of breast-feeding should be weighed against the remote possibility of adverse effects occurring in the infant. Mothers taking Tegretol may breast-feed their infants, provided the infant is observed for possible adverse reactions (e.g. excessive somnolence, allergic skin reaction) [35,45,46,80]. There have been some reports of cholestatic hepatitis in neonates exposed to carbamazepine during antenatal and or during breast feeding. Therefore breast-fed infants of mothers treated with carbamazepine should be carefully observed for adverse hepatobiliary effects [312].

## **9.3 Females and males of reproductive potential**

### **Contraception**

Women of childbearing potential should use effective contraception during treatment with Tegretol and for 2 weeks after the last dose [317]. Due to enzyme induction, Tegretol may result in a failure of the therapeutic effect of oral contraceptive drugs containing oestrogen

and/or progesterone. Therefore, women of child-bearing potential should be advised to use alternative contraceptive methods while on treatment with Tegretol [312].

### **Infertility**

There have been very rare reports of impaired male fertility and/or abnormal spermatogenesis [295].

## **10 Overdosage**

### **Signs and symptoms [50,151-154]**

The presenting signs and symptoms of overdosage usually involve the central nervous, cardiovascular, respiratory systems and the adverse drug reactions mentioned under section 7 Adverse drug reaction [312].

#### **Central nervous system**

CNS depression; disorientation, depressed level of consciousness, somnolence, agitation, hallucination, coma; blurred vision, slurred speech, dysarthria, nystagmus, ataxia, dyskinesia, initially hyperreflexia, later hyporeflexia; convulsions, psychomotor disturbances, myoclonus, hypothermia, mydriasis [229,312].

#### **Respiratory system**

Respiratory depression, pulmonary edema.

#### **Cardiovascular system**

Tachycardia, hypotension, at times hypertension, conduction disturbance with widening of QRS complex; syncope in association with cardiac arrest.

#### **Gastrointestinal system**

Vomiting, delayed gastric emptying, reduced bowel motility.

#### **Musculoskeletal system**

There have been some cases which reported rhabdomyolysis in association with carbamazepine toxicity [312].

#### **Renal function**

Retention of urine, oliguria or anuria; fluid retention, water intoxication due to an ADH-like effect of carbamazepine.

### **Laboratory findings**

Hyponatremia, possibly metabolic acidosis, possibly hyperglycemia, increased muscle creatine phosphokinase.

### **Management [50,151-154,158]**

There is no specific antidote.

Management should initially be guided by the patient's clinical condition; admission to hospital. Measurement of the plasma level to confirm carbamazepine poisoning and to ascertain the size of the overdose.

Evacuation of the stomach, gastric lavage, and administration of activated charcoal. Delay in evacuating the stomach may result in delayed absorption, leading to relapse during recovery from intoxication [230-233]. Supportive medical care in an intensive care unit with cardiac monitoring and careful correction of electrolyte imbalance.

### **Special recommendations**

Charcoal hemoperfusion has been recommended. Hemodialysis is the effective treatment modality in the management of the carbamazepine overdose [312].

Relapse and aggravation of symptomatology on the 2<sup>nd</sup> and 3<sup>rd</sup> day after overdose, due to delayed absorption, should be anticipated.

## **11 Clinical pharmacology**

### **Pharmacotherapeutic group, ATC**

Therapeutic class: antiepileptic, neurotropic, and psychotropic agent; (ATC Code: N03 AF01).

Dibenzazepine derivative.

### **Mechanism of action (MOA)**

The mechanism of action of carbamazepine, the active substance of Tegretol, has only been partially elucidated [54]. Carbamazepine stabilizes hyperexcited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses [54]. It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarized neurons via use- and voltage-dependent blockade of sodium channels may be its main mechanism of action [215-217].

Whereas reduction of glutamate release and stabilization of neuronal membranes may account mainly for the antiepileptic effects, the depressant effect on dopamine and noradrenaline turnover could be responsible for the antimanic properties of carbamazepine [173,174].

## Pharmacodynamics (PD)

As an antiepileptic agent its spectrum of activity embraces: partial seizures (simple and complex) with and without secondary generalization; generalized tonic-clonic seizures, as well as combinations of these types of seizures [24,35,47,48,56-58].

In clinical studies Tegretol given as monotherapy to patients with epilepsy - in particular children and adolescents - has been reported to exert a psychotropic action [24,47,52,63,97,166,172,177,223], including a positive effect on symptoms of anxiety and depression [52,78,168,169,176] as well as a decrease in irritability and aggressiveness [47b,52,169,176,177]. As regards cognitive and psychomotor performance, in some studies equivocal or negative effects, depending also upon dosages administered, were reported [18,74,166,167,170,197,198]. In other studies, a beneficial effect on attentiveness, cognitive performance/memory was observed [52,53,169,170,172,176,177,198,199].

As a neurotropic agent Tegretol is clinically effective in a number of neurological disorders, e.g. it prevents paroxysmal attacks of pain in idiopathic and secondary trigeminal neuralgia [22,33,210]; in addition, it is used for the relief of neurogenic pain in a variety of conditions, including tabes dorsalis, post-traumatic paresthesia, and post-herpetic neuralgia [209]; in alcohol withdrawal syndrome it raises the lowered convulsion threshold and improves withdrawal symptoms (e.g. hyperexcitability, tremor, impaired gait) [47b,98,150]; in diabetes insipidus centralis, Tegretol reduces the urinary volume and relieves the feeling of thirst [48,155].

As a psychotropic agent Tegretol proved to have clinical efficacy in affective disorders, i.e. as treatment for acute mania as well as for maintenance treatment of (manic-depressive) bipolar affective disorders, when given either as monotherapy or in combination with neuroleptics, antidepressants, or lithium [50,51,59,60,61,64,82,156,157], in excited schizo-affective disorder and excited mania in combination with other neuroleptics, and in rapid cycling episodes [211213].

## Pharmacokinetics (PK) Absorption

Carbamazepine is absorbed almost completely but relatively slowly from the tablets [1,14]. The conventional tablets and the chewable tablets yield mean peak plasma concentrations of the unchanged substance within 12 and 6 hours, respectively, following single oral doses [2,3]. With the oral suspension, mean peak plasma concentrations are attained within 2 hours [1,4], and with the suppositories within a mean of 12 hours [200-202]. With respect to the amount of active substance absorbed, there is no clinically relevant difference between the oral dosage forms [8,9]. After a single oral dose of 400 mg carbamazepine (tablets) the mean peak concentration of unchanged carbamazepine in the plasma is approx. 4.5 micrograms/mL [2,3].

When CR tablets are administered singly and repeatedly, they yield about 25% lower peak concentrations of active substance in plasma than the conventional tablets; the peaks are attained within 24 hours. The CR tablets provide a statistically significant decreased fluctuation index, but not a significant decreased  $C_{\min}$  at steady state. The fluctuation of the plasma concentrations

with a twice-daily dosage regimen is low. The bioavailability of Tegretol CR tablets is about 15% lower than that of the other oral dosage forms [2,5-7,62,171].

When suppositories are administered, the amount of carbamazepine absorbed is about 25% lower than with tablets [200]. No change of fluctuation index, but slight decrease of  $C_{\max}$  and  $C_{\min}$  compared to tablets was found at steady state [203-205]. For doses up to 300 mg carbamazepine about 75% of the total amount absorbed reaches the general blood circulation within 6 hours after application [201,202]. The result has led to the recommendation that the maximal daily dose be limited to 250 mg q.i.d.

Steady-state plasma concentrations of carbamazepine are attained within about 1 to 2 weeks, depending individually upon auto-induction by carbamazepine and hetero-induction by other enzyme-inducing drugs, as well as on pretreatment status, dosage, and duration of treatment [55].

The steady-state plasma concentrations of carbamazepine considered as 'therapeutic range' vary considerably interindividually: for the majority of patients a range between 4 to 12 micrograms/mL corresponding to 17 to 50 micromol/L has been reported. Concentrations of carbamazepine-10,11-epoxide (pharmacologically active metabolite): about 30% of carbamazepine levels [1,7,10,11,16,21,22,33,44].

Ingestion of food has no significant influence on the rate and extent of absorption, regardless of the dosage form of Tegretol [8,9].

### **Distribution**

Assuming complete absorption of carbamazepine, the apparent volume of distribution ranges from 0.8 to 1.9 L/kg [1,10-13,33,44].

Carbamazepine crosses the placental barrier [33].

Carbamazepine is bound to serum proteins to the extent of 70 to 80% [1,10-13]. The concentration of unchanged substance in cerebrospinal fluid and saliva reflects the non-protein bound portion in the plasma (20 to 30%). Concentrations in breast milk were found to be equivalent to 25 to 60% of the corresponding plasma levels.

### **Biotransformation/metabolism**

Carbamazepine is metabolized in the liver, where the epoxide pathway of biotransformation is the most important one, yielding the 10,11-transdiol derivative and its glucuronide as the main metabolites. Cytochrome P450 3A4 has been identified as the major isoform responsible for the formation of the pharmacologically active carbamazepine-10,11 epoxide from carbamazepine. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide [301]. 9-Hydroxy-methyl-10-carbamoyl acridan is a minor metabolite related to this pathway [16]. After a single oral dose of carbamazepine about 30% appears in the urine as end-products of the epoxide pathway [14]. Other important biotransformation pathways for carbamazepine lead

to various monohydroxylated compounds, as well as to the N-glucuronide of carbamazepine produced by UGT2B7 [14,16,294].

## Elimination

The elimination half-life of unchanged carbamazepine averages approx. 36 hours following a single oral dose, whereas after repeated administration it averages only 16 to 24 hours (autoinduction of the hepatic mono-oxygenase system), depending on the duration of the medication. In patients receiving concomitant treatment with other liver-enzyme inducing drugs (e.g. phenytoin, phenobarbitone), half-life values averaging 9 to 10 hours have been found [14,16,44].

The mean elimination half-life of the 10,11-epoxide metabolite in the plasma is about 6 hours following single oral doses of the epoxide itself [15].

After administration of a single oral dose of 400 mg carbamazepine, 72% is excreted in the urine and 28% in the feces [14,16]. In the urine, about 2% of the dose is recovered as unchanged drug and about 1% as the pharmacologically active 10,11-epoxide metabolite [14,16].

## Special populations

### Pediatric patients

Owing to enhanced carbamazepine elimination, children may require higher doses of carbamazepine (in mg/kg) than adults [1,17-19].

### Geriatric patients (65 years or above)

There is no indication of altered pharmacokinetics of carbamazepine in elderly patients as compared with young adults [20].

### Patients with hepatic or renal impairment

No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.

## 12 Clinical studies

No recent clinical trials have been conducted with Tegretol.

## 13 Non-clinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, genotoxicity and carcinogenic potential. However, the animal studies were insufficient to rule out a teratogenic effect of carbamazepine [314].

### Rectal local toxicity

The local tolerability of carbamazepine suppositories administered by the rectal route to rabbits once daily for 2 weeks was not different to control animals receiving vehicle only.

### **Carcinogenicity**

In rats treated with carbamazepine for 2 years, there was an increased incidence of hepatocellular tumors in females and benign testicular tumors in males. However, there is no evidence that these observations are of any relevance to the therapeutic use of carbamazepine in humans. **Genotoxicity**

Carbamazepine was not found to be genotoxic in various standard bacterial and mammalian mutagenicity studies. **Reproductive toxicity**

For reproductive toxicity, see section 9 Pregnancy, lactation, females and males of reproductive potential.

## **14 Pharmaceutical information**

**Incompatibilities** None

known.

### **Special precautions for storage**

Tablets: do not store above 25°C, protect from moisture.

CR tablets: do not store above 25°C protect from moisture.

Chewable tablets: protect from heat (do not store above 30°C) and protect from moisture.

Oral suspension: protect from heat (do not store above 30°C) and protect from light.

Suppositories: protect from heat (do not store above 30°C).

Information might differ in some countries.

Tegretol must be kept out of the reach and sight of children.

**Instructions for use and handling**

There is no specific instruction for use/handling.

## 15 References

### Including references (26-47) Pregnancy and Lactation and Reproduction Toxicity (BDI 05 July 89)

1. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. *Clin Pharmacokinet* 1986;11:177-98.
2. G 32 883 Carbamazepin, TEGRETOL. Comparison of the SR DIVITABS formulation to TEGRETOL tablets. Report from Pharmacological Chemistry, B 27/1985. Ciba-Geigy Ltd. Basle, Switzerland. 10 June 85.
3. Chan KKH, Sawchuk RJ, Thompson TA, Redalieu E, Wagner WE, Leshner AR, et al. Bioequivalence of carbamazepine chewable and conventional tablets: single-dose and steady-state studies. *J Pharm Sci* 1985;74(8):866-70.
4. Wada JA, Troupin AS, Friel P, Remick R, Leal K, Pearmain J. Pharmacokinetic comparison of tablet and suspension dosage forms of carbamazepine. *Epilepsia* 1978;19:251-5.
5. Besser R, Katzmann K, Krämer G. Carbamazepin retard in der Epilepsitherapie. Vergleich der Tagesprofile unter zwei verschiedenen Präparaten. *Akt Neurol* 1985;12:75-7.
6. Krämer G, Besser R, Katzmann K, Theisohn M. Carbamazepin retard in der Epilepsitherapie. Vergleich der Tagesprofile unter konventionellem Carbamazepin und Carbamazepin retard. *Akt Neurol* 1985;12:70-4.
7. Dubois JP, Dörhöfer G, Henriksen O, Hulsman JRAJ, Johannessen SI, Racine A, Theobald W. Entwicklung des Tegretal retard – kinetisch orientierte Konzeption. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:212-21.
8. G 32 883 Carbamazepine, Tegretol. Assessment of a possible influence of food on the performance of controlled-release tablets (TEGRETOL CR). Report from Pharmacological Chemistry, B 13/1987. Ciba-Geigy Ltd. Basle, Switzerland. 28 Jan 87.
9. G 32 883 Carbamazepine, Tegretol. Influence of food on the bioavailability of carbamazepine in 4 healthy volunteers given orally either one 200 mg Tegretol conventional tablet or one 200 mg Controlled Release Divitabs and a 2% suspension of 100 mg of 15N-carbamazepine 2 hours before. Report from Biopharmaceutical Research Center, CRB R 48/1988. Laboratoires Ciba-Geigy SA. Rueil Malmaison, France. 18 Aug 88.
10. Bertilsson L. Clinical pharmacokinetics of carbamazepine. *Clin Pharmacokinet* 1978;3:128-43.
11. Morselli PL, Franco-Morselli R. Clinical pharmacokinetics of antiepileptic drugs in adults. *Pharmacol Ther* 1980;10:65-101.
12. Morselli PL, Bossi L, Gerna M. Pharmacokinetic studies with carbamazepine in epileptic patients. In: Birkmayer W, editor. *Epileptic seizures-behaviour-pain*. Bern: Hans Huber Publisher, 1976:141-50.
13. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. *Clin Pharmacokinet* 1976;1:161-88.
14. Faigle JW, Feldmann KF. Carbamazepine. Biotransformation. In: Woodbury DM, Penry JK, Pippenger CE, editors. *Antiepileptic drugs*. New York: Raven Press, 1982:483-95.

15. Tomson T, Tybring G, Bertilsson L. Single-dose kinetics and metabolism of carbamazepine 10,11-epoxide. *Clin Pharmacol Ther* 1983;33(1):58-65.
16. Faigle JW, Feldmann KF. Carbamazepine: Biotransformation. In: Levy RH, Mattson RH, Penry JK, Dreifuss FE, Meldrum BS, editors. *Antiepileptic drugs*. New York: Raven Press, 1989:491-504.
17. Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. *Clin Pharmacol Ther* 1980;27:83-8.
18. Riva R, Contin M, Albani F, Perucca E, Procaccianti G, Baruzzi A. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and pheno-barbitone co-medication. *Clin Pharmacokinet* 1985;10:524-31.
19. De Michele G, Brescia Morra V, Pisanti N, Giani U, Filla A, Sinisi L et al. Carbamazepine serum levels in epileptics. Influence of age, sex, body weight and interaction with phenobarbital. *Acta Neurol* 1985;7:228-34.
20. Hockings N, Pall A, Moody J, Davidson AVM, Davidson DLW. The effects of age on carbamazepine pharmacokinetics and adverse effects. *Br J Clin Pharmacol* 1986;22:725-8.
21. Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: Goodman and Gilman's, editor. *The pharmacological basis of therapeutics*. New York: Macmillan, 1985:1673-4.
22. Browne TR. Epilepsy in adolescents and adults. In: Rakel RE, editor. *Conn's current therapy*. Philadelphia: Saunders, 1989:781-2,786-7,821-2.
23. Krämer G. Carbamazepin-induzierte Veränderungen von Laborparametern und ihre klinische Relevanz. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:107-29.
24. Kruse R. Stellenwert des Carbamazepins in der antiepileptischen Langzeit-Therapie bei Kindern und Jugendlichen. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:156-69.
25. Krämer G, Bork K. Dermatologische Nebenwirkungen von Carbamazepin. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:130-41.
26. Review of Reproduction Studies with G 32 883 (Tegretol). Ciba-Geigy Ltd. Basle, Switzerland. 07 Aug 72.
27. G 32 883 – Reproduction Study, Rat, Segment II. Ciba-Geigy Ltd. Basle, Switzerland. 19 Apr 74.
28. G 32 883 – Reproduction Study, Mouse, Segment II. Ciba-Geigy Ltd. Basle, Switzerland. 14 Mar 74.
29. Sullivan FM, McElhatton PR. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin and primidone in mice. *Toxicol Appl Pharmacol*. 1977;40:365-78.
30. Yerby Ms. Problems and management of the pregnant woman with epilepsy. *Epilepsia* 1987;28 Suppl 3:S29-S36.
31. Brodie MJ. Epilepsy, anticonvulsants and pregnancy. In: Ross E, Chadwick D, Crawford R, editors. *Epilepsy in young people*. Chichester John Wiley & Sons Ltd, 1987:81-92.

32. Lindhout D, Höppener RJE, Meinardi H. Teratogenic of antiepileptic drug combination with special emphasis on epoxidation of carbamazepine. *Epilepsia* 1984;25:77-83.
33. Reynolds JEF, editor. *Antiepileptics. The extra pharmacopoeia*. London: The Pharmaceutical Press, 1989:400-12.
34. Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: A prospective study. *Ann Neurol* 1987;21:176-82.
35. Kruse R. Stellenwert des Carbamazepins in der antiepileptischen Langzeit-Therapie bei Kindern und Jugendlichen. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag 1987:156-69.
36. Fröscher W. Epilepsie-Therapie bei Erwachsenen: Trends, Stellenwert des Carbamazepins. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag 1987:170-82.
37. Kaneko S, Otani K, Fukushima Y, Ogawa Y, Nomura Y, Ono T, et al. Teratogenicity of antiepileptic drugs: Analysis of possible risk factors. *Epilepsia* 1988;29:459-67.
38. Dalessio DJ. Seizure disorders and pregnancy. *N Engl J Med* 1985;312:559-63.
39. Jones KL, Lacro RV, Johnson K, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. *N Engl J Med* 1989;320(25):1661-6.
40. Firtz H, Müller D, Hess R. Comparative study of the teratogenicity of phenobarbitone, diphenylhydantoin and carbamazepine in mice. *Toxicology* 1976;6:323-30.
41. Finnell RH, Mohl VK, Bennett GD, Taylor SM. Failure of epoxide formation to influence carbamazepine-induced teratogenesis in a mouse model. *Teratogenesis, Carcinogenesis, and Mutagenesis* 1986;6:393-401.
42. Niesen M, Fröscher W. Finger- and toenail hypoplasia after carbamazepine monotherapy in late pregnancy. *Neuropediatrics* 1985;16:167-8.
43. Pynnönen S, Kanto J, Sillanpää M, Erkkola R. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. *Acta Pharmacol Toxicol* 1977;41:244-53.
44. Froescher W, Eichelbaum M, Niesen M, Dietrich K, Rasuch P. Carbamazepine levels in breast milk. *Therapeutic Drug Monitoring* 1984;6:266-71.
45. Krämer G. Zur Plasmakonzentration von Carbamazepin: "therapeutischer Bereich" und Nutzen der Bestimmung. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag 1987:44-59.
46. Committee on Drugs. American academy of pediatrics. The transfer of drugs and other chemicals into human breast milk. *Pediatrics* 1983;72:375-83.
- 47.a\* Briggs GG, Freeman RK, Yaffe SJ, editors. Carbamazepine. Anticonvulsant. Fetal Risk Summary. In: *Drugs in pregnancy and lactation*. Baltimore: Williams & Wilkins, 1986:58/c-9c.
- 47.b Sillanpää M. Das klinische Profil von Carbamazepin Nutzen, Risiken und Optimierung der Therapie. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:92-106.
48. Sillanpää M. Carbamazepine. Pharmacology and clinical uses. *Acta Neurol Scand* 1981;64 Suppl 88:69-90,111-2,125-7,145-60.

49. AMA Drug Evaluations. Antiepileptic drugs. Chicago: American Medical Association, 1986:169-95.
50. Schmidt St, Greil W. Carbamazepin in der Behandlung psychiatrischer Erkrankungen. Uebersicht zum gegenwärtigen Stand der Forschung. *Nervenarzt* 1987;58:719-36.
51. Demisch K, Bellaire W, Stoll KD. Carbamazepin in der Prophylaxe rezidivierender affektiver Psychosen. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. *Carbamazepin in der Psychiatrie*. Stuttgart: Georg Thieme Verlag, 1989:134-41.
52. Blank R. Carbamazepin und seine psychischen Wirkungen bei Kindern und Jugendlichen. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. *Carbamazepin in der Psychiatrie*. Stuttgart: Georg Thieme Verlag, 1989:218-24.
53. Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. *Epilepsia* 1982;23:531-44.
54. Schmutz M, Klebs K, Mondadori C, Olpe HR. Das pharmakologische Profil des Carbamazepin. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:4-13.
55. Mikati MA, Browne TR, Collins JF. Time course of carbamazepine autoinduction. *Neurology* 1989;39:592-4.
56. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. *New Engl J Med* 1985;313:145-51.
57. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. *J Neurol Neurosurg Psychiatry* 1985;8:639-44.
58. Chadwick D, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonicclonic seizures. *J Neurol Neurosurg Psychiatry* 1985;48:1073-7.
59. Gonçalves N. Carbamazepin bei affektiven Störungen unter besonderer Berücksichtigung manischer Syndrome. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. *Carbamazepin in der Psychiatrie*. Stuttgart: Georg Thieme Verlag, 1989:95-9.
60. Stoll KD, Haas S. Der antimanische Effekt des Carbamazepins: Evaluation unter Bezug auf methodische Aspekte. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. *Carbamazepin in der Psychiatrie*. Stuttgart: Georg Thieme Verlag, 1989:86-94.
61. Placidi GF, Lenzi A, Lazzarini F, Cassano GB, Akiskal HS. The comparative efficacy and safety of carbamazepine versus lithium, a randomized, double-blind 3-year trial in 83 patients. *J Clin Psychiatry* 1986;47:490-4.
62. G 32 883 – CR TEGRETOL Divitabs 200/400 mg. Clinical assessment. Report from Clinical Research, TL/DT 3, TL/DT 4. Ciba-Geigy Ltd. Basle, Switzerland. 20 Mar 87.
63. Blankenhorn V, Bülow P, Krämer G, Kreiten K, Stefan H. Tegretal 400 retard versus Tegretal 200 in der Behandlung schwerverlaufender partieller Epilepsien. Eine Einjahresstudie. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:254-8.
64. Ballenger JG. The use of anticonvulsants in manic-depressive illness. *J Clin Psychiatry* 1988;9:21-4.

65. Krämer G, Besser R, Schlander M. Carbamazepin: Nebenwirkungen und Toxizität. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. Carbamazepin in der Psychiatrie. Stuttgart: Georg Thieme Verlag, 1989:233-43.
66. Does the rare possibility of detecting an incipient bone marrow depression in patients receiving carbamazepine for more than four months justify the expense hematological monitoring? *International Drug Therapy Newsletter* 1988;23:35.
67. Davies-Jones GAB. Anticonvulsants. Complications of anticonvulsant therapy as such. In: Dukes MNG, editor. *Meyler's side effects of drugs* 11th edition. Amsterdam: Elsevier, 1988: 120-36.
68. Verspohl EJ. Antiepileptika. In: Ammon HPT, editor. *Arzneimittelneben- und -wechselwirkungen*. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1986:399,4079,412,414-5.
69. Krämer G, Besser R, Theisohn M. Interaktionen von Carbamazepin mit anderen Medikamenten. In: Krämer G, Hopf HC, editors. Carbamazepin in der Neurologie. Stuttgart: Georg Thieme Verlag, 1987:70-90.
70. Eales L. Porphyria and the dangerous life-threatening drugs. *S Afr Med J* 1979;56:914.
71. Yeung Laiwah AAC, Raperort WG, Thompson GG, Macphee GJA, Philip MF, Moore MR, et al. Carbamazepine-induced non-hereditary acute porphyria. *Lancet* 1983;i:790-2.
72. Schmidt St, Greil W. Hinweise zur praktischen Durchführung einer Behandlung mit Carbamazepin. In: Müller-Oerlinghausen B, Haas S, Stoll KD, editors. Carbamazepin in der Psychiatrie. Stuttgart, Georg Thieme Verlag, 1989:244-50.
73. Silverstein FS, Boxer L, Johnston MV. Hematological monitoring during therapy with carbamazepine in children. *Ann Neurol* 1983;13:685-6.
74. Trimble MR, Cull C. Children of school age: The influence of antiepileptic drugs on behavior and intellect. *Epilepsia* 1988;29 Suppl 3:15-9.
75. Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. *Epilepsia* 1987;28 Suppl 3:S59-S63.
76. Neppe VM, Tucker GJ, Wilensky AJ. Introduction. Fundamentals of carbamazepine use in neuropsychiatry. *J Clin Psychiatry* 1988;49 Suppl 4:4-6.
77. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. *J Clin Psychiatry* 1988;49 Suppl 4:58-61.
78. Trimble MR. Carbamazepine and mood: Evidence from patients with seizure disorders. *J Clin Psychiatry* 1988;49 Suppl 4:7-11.
79. Ippen H, Fuchs Th. Anästhesiologische Probleme bei induzierbaren Porphyrien. *Krankenhausarzt* 1984;57:1165-74.
80. G 32883 Tegretol. Single case file of spontaneous reports on adverse reactions. Ciba-Geigy Ltd. Basle, Switzerland. 29 Nov 92.
81. Davies-Jones GAB. Anticonvulsant drugs. In: Dukes MNG, Beeley L, editors. *Side effects of drugs annual* 12. Amsterdam: Elsevier, 1988:56-7.
82. Post RM, Kramlinger KG, Uhde WT. Carbamazepine-Lithium combination: clinical efficacy and side effects. *Int Drug Ther News Lett* 1987;22:5-8.

83. Joffe RT, Post RM, Uhde TW. Lack of pharmacokinetic interaction of carbamazepine with tranlycypromine. *Arch Gen Psychiatry* 1985;42:738.
84. Terrence CF, Fromm G. Congestive heart failure during carbamazepine therapy. *Ann Neurol* 1980;8:200-1.
85. De Swert LF, Ceuppens JL, Teuwen D, Wijndaele L, Casaer P, Casteels-Van Daele M. Acute interstitial pneumonitis and carbamazepine therapy. *Acta Paediatr Scand* 1984;73:285-8.
- 86.\* Shear NH, Spielberg STP. Anticonvulsant hypersensitivity syndrome, in-vitro assessment of risk. *J Clin Invest* 1988;82:1826-32.
87. Snead OC, Hosey LC Exacerbation of seizures in children by carbamazepine. *N Engl J Med* 1985;313(15):916-21.
88. Horn CS, Ater SB, Hurst DL. Carbamazepine exacerbated epilepsy in children and adolescents. *Pediatr Neurol* 1986;2:340-45.
89. Franceschi M, Ciboddo G, Truci G, Borri A, Canal N. Fatal aplastic anemia in a patient treated with carbamazepine. *Epilepsia* 1985;29:582-3.
90. Pellock JM. Carbamazepine side effects in children and adults. *Epilepsia* 1987;28 Suppl 3:S64-S70.
91. Horowitz S, Patwardhan R, Marcus E. Hepatotoxic reactions associated with carbamazepine therapy. *Epilepsia* 1988;29:149-54.
92. Luoma PV, Myllylä VV, Hokkanen E. Relationship between plasma high-density lipoprotein cholesterol and anticonvulsant levels in epileptics. *J. Cardiovasc Pharmacol* 1982;4:1024-7.
93. O'Neill B, Callaghan N, Stapleton M, Molloy W. Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. *Acta Neurol Scand* 1982;65:104-9.
94. Heldenberg D, Harel S, Holtzman M, Levto O, Tamir I. The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. *Neurology* 1983;33:510-3.
95. Hillebrand G, Castro LA, Van Scheidt W, Beukelmann D, Land W, Schmidt D. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. *Transplantation* 1987;43:9156.
96. Lele P, Peterson P, Yang S, Jarell B, Burke JF. Cyclosporine and Tegretol - another drug interaction □abstract□. *Kidney Int* 1985;27:344.
97. Cano JP, Bun H, Iliadis A, Dravet C, Roger J, Gastaut H. Influence of antiepileptic drugs on plasma levels of clobazam and des methylclobazam: application of research on relations between doses, plasma levels and clinical efficacy. In: Hindmarch I, Stonier PD, editors. *Clobazam. Royal Society of Medicine International Congress Symposium Series No. 43.* London: Academic Press 1981:169-74.
98. Levy RH, Lane EA, Guyot M, Brachet-Liermain A, Cenraud B, Loiseau P. Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. *Drug Metab Disposition* 1983;11:286-92.
99. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. *Clin Pharmacol Ther* 1978;24:316-23.
100. Tatro DS, editor. *Drug interactions facts.* St. Louis: JB Lippincott Company, 1988:176a,376,529,753.

101. Penry K, Dean JC. The scope and use of valproate in epilepsy. *J Clin Psychiatry* 1989;50 Suppl 3:17-22.
102. Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. *Am J Med.* 1988;84 Suppl 1A:29-33.
103. Warren J, Benmann JD, Wannamaker BB, Levy RH. Kinetics of a carbamazepine-ethosuximide interaction. *Clin Pharmacol Ther* 1980;28:646-51.
104. Battino D, Cusi C, Franceschetti S, Moise A, Spina S, Avanzini G. Ethosuximide plasma concentrations: influence of age and associated concomitant therapy. *Clin Pharmacokinet* 1982;7:176-80.
105. Terzano MG, Salati MR, Gemignani F. Asterix associated with carbamazepine. *Acta Neurol Belg* 1983;83:158-65.
106. Penttila O, Neuvonen PJ, Aho K, Lehtovaara R. Interaction between doxycycline and some antiepileptic drugs. *BMJ* 1974;2:470-2.
107. Kanter GL, Yerevanian BI, Ciccone JR. Case report of a possible interaction between neuroleptics and carbamazepine. *Am J Psychiatry* 1984;141:1101-2.
108. Yerevanian BI, Hodgman CH. A haloperidol-carbamazepine interaction in a patient with rapid cycling bipolar disorder. *Am J Psychiatry* 1985;142:785-6.
109. Arana GW, Goff DC, Friedman H, Ornstein M, Greenblatt DJ, Black B et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? *Am J Psychiatry* 1986;143:650-1.
110. Tong TG, Pond SM, Kreek MJ, Jaffery NF, Benowitz NL. Phenytoin-induced methadone withdrawal. *Ann Intern Med* 1981;94:349-51.
111. Schmidt D. Effect of antiepileptic drugs on estrogen and progesterone metabolism and on oral contraception. In: Dam M, Gram L, Penry JK, editors. *In: Advances in Epileptology*. New York: Raven Press, 1981:423-31.
112. Mitchell EA, Dower JC, Green RJ. Interaction between carbamazepine and theophylline. *N Z Med J* 99, 69 f. (1986).
113. Rosenberry KD, Defusco CJ, Mansmann HC, McGeedy SJ. Reduced theophylline half-life induced by carbamazepine therapy. *J Pediatr* 1983;102:472-4.
114. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. *Ann Intern Med* 1981;94:280.
115. Ross JRY, Beeley L. Interaction between carbamazepine and warfarin. *BMJ* 1980;280:1415-6.
116. Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. *Ther Drug Monit* 1987;9:21-3.
117. Zielinski JJ, Haidukewych D, Leheta BJ. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication. *Ther Drug Monit* 1985;7:51-3.
118. Egli M. Pharmakologische Ueberlegungen zur Mono- und Polytherapie. Interaktionen der Antiepileptika untereinander. In: Kruse R, editor. *Epilepsie 84, Antiepileptische Mono- oder Polytherapie, Medizingeschichte*. Reinbeck: Einhorn-Press, 1985:44-9.

119. Dravet C, Mesdjian E, Cenraud B, Roger J. Interaction between carbamazepine and triacetyloleandomycin. *Lancet* 1977;1:810-1.
120. Mesdjian E, Dravet C, Cenraud B, Roger J. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. *Epilepsia* 1980;21:489-96.
121. Friocourt P, Martin Ch. Quel est votre diagnostic. *Concours Med* 1988;110:1445-7.
122. Capewell S, Freestone S, Critchley JAJH, Pottage A. Reduced felodipine bioavailability in patients taking anticonvulsants. *Lancet* 1988;(ii), 480-2.
123. Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. *Dev Med Child Neurol* 1981;23:761-9.
124. McBride MC. Serum carbamazepine levels are increased by acetazolamide. *Ann Neurol* 1984;16:393.
125. Krämer G, Theisohn M, von Unruh GE, Eichelbaum M. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique. *Ther Drug Monit* 1986;8:387-92.
126. Zielinski JJ, Lichten EM, Haiddukewych D. Clinically significant danazol-carbamazepine interaction. *Ther Drug Monit* 1987;9:24-7.
127. Hansten PD, Horn JR. Carbamazepine (Tegretol) – antidepressants, tricyclic. *Drug Interact Newl* 1988;8:35,U-17.
128. Lesser I. Carbamazepine and desipramine: a toxic reaction. *J Clin.Psychiatry* 1984;45:360.
129. Bourgeois BFD, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. *Neurology* 1982;32:1122-6.
130. Besser R, Katzmann, Krämer G, Theisohn M. Nicotinamide is of no value as adjunct in antiepileptic therapy in adults □abstract□. Hamburg: Epilepsy International Congress,1985.
131. Sandyk R. Carbamazepine and metoclopramide interaction: possible neurotoxicity. *BMJ* 1984;288:830.
132. Price WA, Zimmer B. Lithium-carbamazepine neurotoxicity in the elderly. *J Am Geriatr Soc* 1985;33:876-7.
133. Andrus PF. Lithium and carbamazepine. *J Clin Psychiatry* 1984;45:525.
134. Hansten PD, Horn JR, editors. *Drug Interactions. Clinical significance of drug-drug interactions.* Philadelphia: Lea & Febiger, 1989:7,78,121,122.
135. Soman M, Swenson C. A possible case of carbamazepine-induced pancreatitis. *Drug Intell Clin Pharm* 1985;19:925-7.
136. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. *Ther Drug Monit* 1981;3:63-70.
137. Browne TR. Clinical pharmacology of antiepileptic drugs. In: Penry JK, Rakel RE, editors. *Epilepsy: Diagnosis, management, quality of life.* New York: Raven Press, 1986:22-7.
138. Schoeman JF, Elyas AA, Brett EM, Lacelles PT. Altered ratio of carbamazepine-10,11epoxide/carbamazepine in plasma of children: evidence of anticonvulsant drug interaction. *Dev Med Child Neurol* 1984;26:749-55.

139. Johannessen SI, Strandjord RE, Munthe-Kaas AW. Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. *Acta Neurol Scand* 1977;55:506-12.
140. Yassa R, Nastase Ch, Camille Y, Henderson M, Belzile L, Beland F. Carbamazepine, diuretics, and hyponatremia: A possible interaction. *J Clin Psychiatry* 1987;48:281-3.
141. Olivesi A. Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. *Biomed Pharmacother* 1986;40:301-8.
142. Privitera M, Greden JF, Gardner RW, Ritchie J, Carroll BJ. Interference by carbamazepine with the dexamethasone suppression test. *Biol Psychiatry* 1982;17:611-20.
143. Roth S, Ebrahim ZY. Resistance to pancuronium in patients receiving carbamazepine. *Anesthesiology* 1987;66:691-3.
144. Marsden JR. Effect of isotretinoin on carbamazepine pharmacokinetics. *Br J Dermatol* 1988;119:4034.
145. Arana GW, Epstein S, Molloy M, Greenblatt DJ. Carbamazepine-induced reduction of plasma alprazolam concentrations: A clinical case report. *J Clin Psychiatry* 1988;49:448-9.
146. Graves NM, Fuerst RH, Cloyd JC, Brundage RC, Welty TE, Lepik IE. Progabide-induced changes in carbamazepine metabolism. *Epilepsia* 1988;29:775-80.
147. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa. *N Engl J Med* 1982;307:1325-7.
148. Bhatt AD. Isoniazid-carbamazepine - a double drug interaction. *Indian J Tuberc* 1989;36:467.
149. Editorial. Carbamazepine update. *Lancet* 1989;ii:595-7.
150. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. *Am J Psychiatry* 1989;146:61721.
151. Tegretol: overdose. An Information on overdose with Ciba-Geigy pharmaceuticals. CibaGeigy Ltd. Basle, Switzerland. Oct 88.
152. Morrow JI, Routledge PA. Poisoning by anticonvulsants. *Adverse drug React. acute Poison. Revs* 1989;8:97-109.
153. Hoefliger M. Vergiftungen mit Carbamazepine (TEGRETOL). *Schweiz Apoth Ztg* 1987;125:288-93.
154. Weaver D, Camfield P, Fraser A. Carbamazepine overdose: five episodes with clinical and pharmacological observations. *Can J Neurol Sci* 1987;14:248.
155. Hey O, Krämer G, Stoll KD. Carbamazepin bei Diabetes insipidus. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:202-9.
156. Dose M, Bremer DE, Raptis C, Weber M, Emrich HM. Akut antimanische Wirkung von Carbamazepin-Suspension. In: Müller-Oerlinghausen Bhaas S, Stoll KD, editors. *Carbamazepin in der Psychiatrie*. Stuttgart: Gorg Thieme Verlag, 1989:100-4.
157. Stoll KD, Bisson HE, Fischer E, Gammel G, Goncalves N, Kröber HL et al. Carbamazepine versus haloperidol in manic syndromes - First report of a multicentric study in germany. In: Shagass C, et al, editors. *Biological psychiatry*. Amsterdam: Elsevier, 1986:332-4.

158. Ulziel Y, Pomeranz A, Jedeikin R, Wolach B. Acute carbamazepine poisoning and hyponatremia. *Child Nephrol Urol* 1988-1989;9:87-9.
159. Hart RG, Easton DJ. Carbamazepine and hematological monitoring. *Ann Neurol* 1982;11:309-12.
160. Joffe RT, Post RM, Roy-Byrne PP, Uhde TW. Hematological effects of carbamazepine in patients with affective illness. *Am J Psychiatry* 1985;142:1196-9.
161. Henriksen O, Johannessen SI, Munthe-Kaas AW. How to use carbamazepine. In: Morselli PL, Pippenger CE, Penry JK, editors. *Antiepileptic drug therapy in pediatrics*. New York: Raven Press, 1983:237-43.
162. Herrick AL, McColl KEL, Moore MR, Brodie MJ, Adamson AR, Goldberg A. Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity. *Br J Clin Pharmacol* 1989;27:491-7.
163. Stoll KD, Krämer G, Berger A. Tegretal 400 retard bei Epilepsien: Ergebnisse einer Verbundstudie mit 473 Patienten. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag 1987:259-66.
164. Yates P, Stockdill G, McIntyre M. Hypersensitivity to carbamazepine presenting as pseudolymphoma. *J Clin.Pathol* 1986;39:1224-8.
165. Zagnoni PG, Belvedere O, Zaccara G, Muscas GC, Pisani F, Oteri G et al. Conventional vs. controlled-release carbamazepine: a multicentre, doubleblind, cross-over study. 18th International Epilepsy Congress □abstract□. New Delhi: India, 1989.
166. Macphee GJA, McPhail EM, Butler E, Brodie MJ. Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients. *Eur J Clin Pharmacol* 1986;31:195-9.
167. Brodie MJ, McPhail E, Macphee GJA, Larkin JG, Gray JMB. Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. *Eur J Clin Pharmacol* 1987;31:655-60.
168. Andrewes DG, Bullen JG, Tomlinson L, Elwes RDC, Reynolds EH. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. *Epilepsia* 1986;27:128-34.
169. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: A double-blind comparison with phenytoin. *Neurology* 1977;27:1023-8.
170. O'Dougherty M, Wright FS, Cox S, Walson P. Carbamazepine plasma concentration. Relationship to cognitive impairment. *Arch Neurol* 1987;44:863-7.
171. Eeg-Olofsson O, Nilsson HL, Tonny B, Arvidsson J, Grahn PA, Gylje H et al. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slow-release formulations. *J Child Neurol* 1990;5:159-65.
172. Loiseau P, Duche B. Carbamazepine. Clinical use. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, editors. *Antiepileptic drugs*. New York: Raven Press, 1989:533-7.
173. Schmutz M. Tierexperimentelle Befunde zur Wirkung von Carbamazepin bei Alkoholentzug. In: Müller-Oerlinghausen B, Haas S, Stoll KD. *Carbamazepin in der Psychiatrie*. Stuttgart: Georg Thieme Verlag, 1989:53-7.

174. Olpe HR, Schmutz M. Carbamazepine (Tegretol) in psychiatric indications: recent findings on its mechanisms of action. In: Emrich H, Schiowy W, Silverstone T, editors. Carbamazepine and oxcarbazepine in psychiatry. *Int Clin Psychopharmacol* 1990;5 Suppl 1:9-13.
175. Tomson T, Ekberg R, Kihlstrand S, Kinnman J, Lund Hakan, Nielsen O et al. Reduced diurnal fluctuations in carbamazepine plasma concentration by the use of a slow-release formulation. *Journal of Epilepsy* 1989;2:97-101.
176. Loiseau P, Duche B. Carbamazepine. Clinical use. Psychotropic effects in patients with epilepsy. In: Levy RH, Dreifuss, Mattson RH, Meldrum BS, Penry JK, editors. *Antiepileptic drugs*. New York: Raven Press, 541-4.
177. Evans RW, Gualtieri TC. Carbamazepine: A neuropsychological and psychiatric profile. *Clin.Neuropharmacol.* 1985;8:221-41.
178. Gram L, Klosterskov Jensen P. Carbamazepine. Toxicity. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, editors. *Antiepileptic drugs*. New York: Raven Press, 1989:555-65.
179. Hopf HC, Krämer G. Carbamazepin bei Neuralgien. In: Krämer G, Hopf HC, editors. *Carbamazepin in der Neurologie*. Stuttgart: Georg Thieme Verlag, 1987:183-9.

▫ References are no longer cited in the BPI text updated XXX 2005.

#### **References BDI Update 13 March 1991, amended 19 June 1991**

180. Rosa FW. Spina bifida in maternal carbamazepine exposure cohort data. Center for Drug Evaluation and Research / Food and Drug Administration. (Rockville, Maryland 20857).
181. Bod M. Teratogenic evaluation of anticonvulsants in a population based Hungarian material. *Teratology* 1989;40:277.
182. Jones KL. Teratogenic effects of carbamazepine. *N Engl J Med* 1989;321:1480-1.
183. G 32883 Tegretol: Spina bifida association with carbamazepine exposure during pregnancy - a review. Ciba-Geigy Ltd. Basle, Switzerland. Mar 91.
184. Simon LT, Hsu B, Adornato BT. Carbamazepine-induced aseptic meningitis. *Ann Intern Med* 1990;112:627-8.
185. Hilton E, Stroh EM. Aseptic meningitis associated with administration of carbamazepine. *J Infect Dis* 1989;159:363-4
186. Pearson HJ. Interaction of fluoxetine with carbamazepine. *J Clin Psychiatry* 1990;51:126.
187. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. II *J Clin Psychopharmacol* 1990;10:213-7.
188. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ et al. Multivitamin-Folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA* 1989;262:2847-52.
189. Biale Y, Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. *Eur J Obstet Gynecol Reprod Biol* 1984;18:211-6.

190. Herranz JL, Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. *Epilepsia* 1988;29:794-804.
191. G 32883 Tegretol: Single case file of spontaneous reports on adverse reactions. Ciba-Geigy Ltd. Basle, Switzerland [data available upon request].
192. Ogawa Y, Kaneko S, Otani K, Fukushima Y. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. *Epilepsy Res* 1991;8:75-8.
193. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 1991;324:674-6.
194. Hobbins JC. Diagnosis and management of neural-tube defects today. *N Engl J Med* 1991;324:690-1.
195. Mattson RH. General principles. Selection of antiepileptic drug therapy. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, editors. *Antiepileptic drugs*. New York: Raven Press, 1989:111-2.
196. Saunders M. Epilepsy in women of childbearing age. *BMJ* 1989;299:581.
197. Gillham RA, Williams N, Wiedmann KD, Butler E, Larkin JG, Brodie MJ. Cognitive function in adult epileptic patients established on anticonvulsant monotherapy. *Epilepsy Res* 1990;7:219-25.
198. Aman MG, Werry JS, Paxton JW, Turbott SH, Stewart AW. Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication. *Epilepsia* 1990;31:51-60.
199. Seetharam MN, Pellock JM. Risk-benefit assessment of carbamazepine in children. *Drug Safety* 1991;6:148-58.

### References Tegretol Suppositories 18 November 1991

200. G 32 883, Carbamazepine, TEGRETOL. Bioavailability of carbamazepine (CBZ) from 200 mg suppositories in comparison to TEGRETOL 200 mg tablets ex Basle and ex Summit. Plasma concentrations of CBZ and CBZ-epoxide after a single 200 mg dose. Report CRB R 8/1989, Biopharmaceutical Research Center, Laboratoires Ciba-Geigy AS. Rueil-Malmaison, France. 02 Mar 89.
201. G 32 883, Carbamazepine, TEGRETOL. Substitution of TEGRETOL CR or TEGRETOL conventional tablets by carbamazepine suppository. Report B 75/1989, Pharmacological Chemistry, Pharma Research and Development, Ciba-Geigy Ltd. Basle, Switzerland. 03 Aug 89, amended 26 Mar 90.
202. G 32 883, Carbamazepine, TEGRETOL. Dose-kinetics proportionality study: TEGRETOL suppositories 100, 300 and 600 mg. Plasma concentration-time profiles of carbamazepine in six healthy volunteers after single application of one suppository each. Report B 29/1989, Pharmacological Chemistry, Pharma Research and Development, Ciba-Geigy Ltd. Basle, Switzerland. 29 Mar 89.
203. G 32 883, Carbamazepine, TEGRETOL. Open, within-patient comparative pharmacokinetic and tolerability trial of TEGRETOL suppositories vs. TEGRETOL conventional tablets in patients with epilepsy (Clinical Trial Plan No.: TS/EP 1) Report B 34/1991, Pharmacological Chemistry, Pharma Research and Development. Ciba-Geigy Ltd. Basle, Switzerland. 26 Apr 91.

204. 1) G 32 883, Carbamazepine, TEGRETOL. Open, within-patient comparative pharmacokinetic and tolerability trial of TEGRETOL suppositories vs. TEGRETOL CR tablets in patients with epilepsy (Clinical Trial Plan No.: TS/EP 5) Report B 36/1991, Pharmacological Chemistry, Pharma Research and Development, Ciba-Geigy Limited, Basle. 20 Aug 91.
205. 2) G 32 883, Carbamazepine, TEGRETOL. Open, within-patient comparative pharmacokinetic and tolerability trial of TEGRETOL suppositories vs. TEGRETOL CR tablets in children with epilepsy (Clinical Trial Plan No.: TS/EP 4) Report B 35/1991, Pharmacological Chemistry, Pharma Research and Development, Ciba-Geigy Limited, Basle. 29 July 91.

#### **Newly added references BDI 09 December 1992**

206. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. Oxford: University Press, 1991.
207. Delgado-Escueta AV, Janz D. Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy. *Neurology* 1992;42 Suppl 5:14960.

#### **Newly added references BPI 19 May 1998**

208. Carter Snead C, Hosey LC. Exacerbation of seizures in children by carbamazepine. *N Engl J Med* 1985;313:916-921.
209. Rose FC, Johnson FN. Carbamazepine in the treatment of non-seizure disorders: trigeminal neuralgia, other painful disorders, and affective disorders. *Rev Contemp Pharmacother* 1997;8:123-143.
210. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. *Arch Gen Psychiatry* 1984;41:165-170.
211. Okuma T, Yamashita I, Takahashi T, Itoh H, Otsuki S, Watanabe S, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. *Acta Psychiatr Scand* 1989;80:250-259.
212. Dose M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and carbamazepine: results of a controlled study and clinical experiences. *Int Clin Psychopharmacol* 1990;5(Suppl 1):35-42.
213. Brodie MJ, Johnson FN. Carbamazepine in the treatment of seizure disorders: Efficacy, pharmacokinetics and adverse event profile. *Rev Contemp Pharmacother* 1997;8:87-122.
214. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. *Epilepsia* 1995;36(Suppl. 5):S8-S13.
215. Willow M, Catterall WA. Inhibition of binding of [<sup>3</sup>H] batrachotoxinin A20- $\beta$ -benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. *Mol Pharmacol* 1982;22:627-635.
216. Willow M, Gonoi T, Catterall WA. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. *Mol Pharmacol* 1985;27:549-558.

217. Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by anticonvulsant drugs diphenylhydantoin and carbamazepine. *Mol Pharmacol* 1983;25:228-234.
218. O'Grifoa FM, Voris JC. Neuroleptic malignant syndrome associated with carbamazepine. *Southern Medical Journal* 1991;84(11):1378-1380.
219. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. *J Clin Psychiatry* 1989;50(8):295-298.
220. Müller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. *The Lancet* 1988;2:1500.
221. Forte A, Gallinaro L, Montesano G, Turano R, Bertagni A, Illuminati G. A possible case of carbamazepine induced pancreatitis. *European Review for Medical and Pharmacological Sciences* 1996.
222. Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. *Epilepsia* 1992;33(1):119-121.
223. Yoshimura K, Kurashige T. A case of protein-losing gastroenteropathy probably induced by carbamazepine. *Proc. 5<sup>th</sup> meeting Shoni Shinkei Gakkai Kenkyukai* 23.07.94. *Brain and Development* 1995;27(1):60-62.
224. Parayannilam C, Guillot R, Fisch R, Kumar P. Hypersensitivity reactions to multiple antiepileptic drugs. *Ann Allergy Asthma Immunol* 1996;74(1):107.
225. Tateno A, et al. Three cases of partial epilepsy accompanied by hearing disorder during carbamazepine medication. *Shonika Rinsho (Japanese Journal of Pediatrics)* 1993;46(2):322-326
226. Mabuchi K, Hayashi S, Nitta E, Takamori M. Auditory disturbance induced by carbamazepine administration in a patient with secondary generalized seizure. *Rinsho Shinkeigaku (Clin Neurol)* 1995;35(5):553-555.
227. Chaloupka V, Mitchell St, Muirhead R. Observation of a reversible, medication-induced change in pitch perception. *J Acoust Soc Amer* July 1994;96(1):145-149.
228. Pepper M. Analysis of Tegretol Database for Reports of "Pancreatitis, Overdose, and Neonatal withdrawal Syndrome" (11/10/1997).
229. Schmidt ST, Schmitz-Buhl M. Signs and symptoms of carbamazepine overdose. *J Neurol* 1995;242:169-173.
230. Gary NE, Byra WM, Eisinger RP. Carbamazepine poisoning: Treatment by hemoperfusion. *Nephron* 1981;27:202-203.
231. De Zeeuw RA, Westenberg HGM, Van der Kleijn E, Gimbrère JSF. An unusual case of carbamazepine poisoning with a near-fatal relapse after two days. *Clin Toxicology* 1979;14(3):263-269.
232. Fisher RS; Cysyk B. A fatal overdose of carbamazepine: Case report and review of literature. *Clin Toxicology* 1988;26(7):477-486.
233. Sethna M, Solomon G, Cedarbaum J, Kutt H. Successful treatment of massive carbamazepine overdose. *Epilepsia* 1989;30(1):71-73.
234. Debruille C, Robert H, Cottencin O, Regnaut N, Gignac C. Carbamazepine-fluvoxamine interaction: two case reports. *J Pharm Clin* 1994;13:128-130.

235. Bonnet P, Vandel S, Nezelof S, Sechter D, Bizouard P. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? *Therapie* 1992;47(2):165.
236. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. *Br J Clin Pharmacol* 1993;36:615-616.
237. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. *Acta Psychiatr Scand* 1991;84:583-584.
238. Cottencin O, Regnaut N, Thevenon-Gignac C, et al. Interaction carbamazépine-fluvoxamine. Conséquences sur le taux plasmatique de carbamazépine. *Encephale* 1995;21(2):141-145.
239. Bagli M, Rao ML, Sobanski T, Laux G. Influence of co-medication on fluvoxamine serum concentration in psychiatric inpatients. *J Neurol Transm Gen Sect (A)* 1995;102(3):III.
240. Wagner W, Vause EW. Fluvoxamine. A Review of Global Drug-Drug Interaction Data. *Clin Pharmacokinet (NZ)* 1995;29(suppl 1):26-32.
241. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. *Intl Clin Psychopharmacol* 1996;11(suppl 5):31-61.
242. Keller Ashton A, Wolin RE. Nefazodone-Induced Carbamazepine Toxicity. *Am J Psychiatry* 1996;153(5):733.
243. Puzantian T, Shaw RJ. Nefazodone and Symptoms Suggesting Neurotoxicity: A Case Report. *J Clin Psychiatry* 1996;57(12):595.
244. Greene DS, Barbhैया RH. Clinical Pharmacokinetics in Nefazodone. *Clin Pharmacokinet Oct* 1997;33(4):260-275
245. Davis R, Whittington R, Bryson HM. Nefazodone. A Review of its Pharmacology and Clinical Efficacy in the Management of Major Depression. *Drugs* 1997;53(4):608-636
246. Albani F, Riva R, Baruzzi A. Clarithromycin-Carbamazepine Interaction: A Case Report. *Epilepsia* 1993;34(1):161-162.
247. Tatum WO, Gonzalez MA. Carbamazepine toxicity in an epileptic induced by clarithromycin. *Hospital Pharmacy* 1994;29(1):45-46.
248. Amsden GW. Macrodiles versus azalides: A drug interaction update. *Annals Pharmacother* 1995;29:906-917.
249. Spina E, Arena D, Scordo MG, Fazio A, Pisani F, Perucca E. Elevation of plasma carbamazepine concentrations in patients with epilepsy. *Ther Drug Monit* 1997;19(5):535-538.
250. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. In Vitro Prediction of the Terfenadine-Ketoconazole Pharmacokinetic Interaction. *J Clin Pharmacol* 1994;34:1222-1227.
251. Hirschfeld S, Jarosinski P. Drug Interaction of Terfenadine and Carbamazepine. *Ann Intern Med* 1993;118(11):907-908.
252. Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. *Pediatrics* 1991;87(2):186-189.
253. Browne TR, Feldman RG, Buchanan RA, et al. Methsuximide for complex partial seizures. Efficacy, toxicity, clinical pharmacology, and drug interactions. *Neurology (USA)* April 1983;33(4):414-418.

254. Norris AE, Dilsaver SC, Del Medico VJ. Carbamazepine treatment of psychosis. *J psychosoc Nurs ment Hlth Serv* Dec 1990;28(12):13-18.
255. Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. *Xenobiotica* 1993;23(3):307-315.
256. Neef C, de Voogd-van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. *Clin Pharmacol Ther* Apr 1988;43(4):372-375.
257. Perez Nahum M, Weyl Ben Arush M, Robinson E. Reduced plasma carbamazepine level during chemotherapy in a child with malignant lymphoma. *Acta Paediatr Scand* 1990;79:873875.
258. Wagner ML, Rimmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its major metabolites. *Clin Pharmacol & Ther* 1993;53(5):536-543.
259. Howard JR, Dix RK, Shumaker RC, Perhach JL. The Effect of Felbamate on Carbamazepine Pharmacokinetics. *Epilepsia* 1992;33(suppl 3):84-85.
260. Albani F, Theodore WH, Washington P. et al. Effect of Felbamate on Plasma Levels of Carbamazepine and Its Metabolites. *Epilepsia* 1991;32(1):130-132.
261. Wagner ML, Graves NM, Marienau K, Holmes GB, Rimmel RP, Leppik IE. Discontinuation of Phenytoin and Carbamazepine in Patients Receiving Felbamate. *Epilepsia* 1991;32(3):398406.
262. Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of Felbamate on Phenytoin and Carbamazepine Serum Concentrations. *Epilepsia* 1989;30(2):225-229.
263. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, et al. Acute Effects of Lamotrigine (BW430C) in Persons with Epilepsy. *Epilepsia* 1986;27(3):248-254.
264. Eriksson AS, Hoppu K, Nergardh A, Boreus L. Pharmacokinetic Interactions Between Lamotrigine and Other Antiepileptic Drugs in Children with Intractable Epilepsy. *Epilepsia* 1996;37(8):769-773.
265. Kaneko T, Hayashimoto A, Niwayama H, Fukushima Y. Effects of zonisamide on serum levels of phenytoin and carbamazepine. *Tenkan Kenkyu (J Japan Epilepsy Soc) (J)* 1993;11:31.
266. Abo J, Miura H, Takashi S, et al. Drug interaction between zonisamide and carbamazepine: a pharmacokinetic study in children with cryptogenic localization-related epilepsies. *Epilepsia (USA)* 1995;36(suppl 3):S162.
267. Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. *Ther Drug Monit* 1986;8(3):293-296
268. Ijiri Y, Oi K, Suzuki K, Fukuoka E, Yoshinari S. Interactions of zonisamide and other drugs. *TDM Kenkyu (Jap J ther Drug Monit) (J)* 1993;10(1):51-56
269. Mengel H. Tiagabine. *Epilepsia* 1994;35(suppl 5):S81-S84
270. Natsch St, Hekster YA, Keyser A, Deckers CLP, Meinardi H, Renier WO. Newer anticonvulsant drugs. Role of pharmacology, drug interactions and adverse reactions in drug choice. *Drug Safety* 1997;17(4):228-240.
271. Doose DR, Walker SA, Sachdeo R, Kramer LD, Nayak RK. Steady-state pharmacokinetics of Tegretol® (Carbamazepine) and Topamax™ (topiramate) in patients with epilepsy on monotherapy, and during combination therapy. *Epilepsia* 1994;35(suppl 8):54.

272. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-State Pharmacokinetics of Topiramate and Carbamazepine in Patients with Epilepsy During Monotherapy and Concomitant Therapy. *Epilepsia* 1996;37(8):774-780.
273. Jerling M. Kinetic interactions between amitriptyline/nortriptyline and other drugs in the light of the CYP2D6-dependence. A population study. *Ther Drug Monit* 1993;15(2):142-143.
274. Jerling M, Bertilsson L, Sjöqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. *Ther Drug Monit* 1994;16(1):1-12
275. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. *J Clin Psychopharmacol* 1991;11(5):313-318.
276. Brøsen K, Kragh-Sørensen P. Concomitant intake of nortriptyline and carbamazepine. *Ther Drug Monit* 1993;15(3):258-260
277. Ketter TA, Flockart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS, Callahan AM. The emerging role of cytochrome P450 3A in psychopharmacology. *J Clin Psychopharmacol*. 1995; 15(6): 387-398
278. De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. *Biol Psychiat* 1992;32(4):369-3.
279. Gerson GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of post-herpetic neuralgia. *Postgrad Med J* 1977;53(suppl 4):104-109.
280. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and Plasma Levels of Clozapine. *Am J Psychiatry* 1993;150(1):169.
281. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. *pharmacopsychiatry* 1995;28(1):26-28.
282. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine Inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. *Ther Drug Monit* 1994;16(4):368-374.
283. Prescott LF, Critchley JAJH, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. *Br J Clin Pharmacol* 1981;12:149-153.
284. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. *Clin Pharmacol Ther* 1984a;35:480-486
285. Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. *Brit J Clin Pharmacol* 1979;7(2):201-206.
286. Neuvonen PJ, Lehtovaara R, Bardy A, Elomaa E. Antipyretic analgesics in patients on antiepileptic drug therapy. *Eur J Clin Pharmacol* 1979;15(4):263-268.
287. Commission on Classification and Terminology, International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. *Epilepsia* 1981; 22:489-501.
288. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. *N Eng J Med* 1994; 331:1272-1285.

289. Roujeau J.C., Kelly J.P., Naldi L., Rzany B., Stern R.S. et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Eng J Med* 1995; 1600-1607.
290. Askmark H., Wiholm B.E. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. *Acta Neurol Scand* 1990; 81:131-140.
291. Tennis P., Stern S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. *Neurology* 1997.
292. Mattson RH. Carbamazepine. In: Engel J, Jr., Pedley TA, editors. *Epilepsy. A comprehensive textbook*. New York, Lippincott-Raven, Volume II:1491-1502

### **Newly added reference BPI amendment 17 December 2001**

293. Tegretol/Carbamazepine. Safety Assessment. Novartis Pharma AG. Basel, Switzerland. 16 Nov 01.

### **Newly added references BPI update 05 May 2006**

294. Schiller H, Marbach P (2006) *Comprehensive Pharmacokinetics Evaluation*. Novartis Pharma AG. Basel, Switzerland. 27 Apr 2006.
295. Michel C (2006) *Comprehensive Medical Safety Evaluation*. Novartis Pharma AG. Basel, Switzerland. 27 Apr 2006.
296. Sturm Y (2006) *Clinical Expert Statement*. Novartis Pharma AG. Basel, Switzerland. 27 Apr 2006.

### **Newly added references BPI amendment 19-Jun-07**

297. [\[Camisasca R, Souppart C \(2007\)\]](#) Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Drug-drug interactions with paroxetine and levetiracetam. Section 4.5 Interaction with other medicinal products and other forms of interaction. Novartis Pharma AG, Basel, Switzerland. 08-May-2007.
298. [\[Camisasca R \(2007\)\]](#) Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Hypogammaglobulinaemia. Section 4.8 Undesirable effects. Novartis Pharma AG, Basel, Switzerland. 08-May-2007.
- 299.\* [\[Camisasca R, Meyer J, Cid J \(2007\)\]](#) Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Stevens Johnson Syndrome and Toxic Epidermal Necrolysis in Asian countries. Section 4.4 Special warnings and precautions for use. Novartis Pharma AG, Basel, Switzerland. 08-May-2007.

3) \*Ref. 299 has been superseded by Ref. 300

### **Newly added references BPI amendment 14-Dec-07**

- \*300. [\[Camisasca R, Meyer J, Cid J \(2007\)\]](#) Tegretol. Clinical expert statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Stevens Johnson Syndrome and Toxic Epidermal Necrolysis in Asian countries. Section 4.4 Special warnings and precautions for use. Novartis Pharma AG, Basel, Switzerland. 4-Dec-07.
301. [\[Camisasca R, Souppart C \(2007\)\]](#) Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Drug-drug interactions Section 4.5 Interaction with other medicinal products and other forms of interaction. Novartis Pharma AG, Basel, Switzerland. 4-Dec-07.

302. [Camisasca R (2007)] Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Hirsutism. Section 4.8 Undesirable effects. Novartis Pharma AG, Basel, Switzerland. 4-Dec-07.
303. [Pisani F, Narbone MC, Fazio A, et al (1984)] Effect of viloxazine on serum carbamazepine levels in epileptic patients. *Epilepsia*;25(4)482-485
304. [Pisani F, Fazi A, Oteri G et al. (1986)] Carbamazepine-viloxazine interaction in patients with epilepsy. *J Neurol Neurosurg Psych*;49:1142-1145

### **Newly added references BPI amendment 27-Nov-08**

305. Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Suicidal ideation and behaviour. Novartis Pharma AG, Basel, Switzerland. 28-Oct-08

### **Newly added references BPI amendment 17-Aug-09**

306. Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – Drug drug interaction. Section 4.5 Interaction with other medicinal products and other forms of interaction. Novartis Pharma AG, Basel, Switzerland. 21-Jul-09
307. Tegretol. Clinical safety statement. Rationale for changes to Novartis Core Data Sheet (CDS) – VBDS. Novartis Pharma AG, Basel, Switzerland. 21-Jul-09

### **Newly added references - BPI amendment 08-Sep-2011**

308. Tegretol. 2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Product Information – DRESS, AGEP and Interactions: tacrolimus, cyclophosphamide, lapatinib and aripiprazole. Novartis. 11-Aug-2011
309. Tegretol. 2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) / Product Information – Carbamazepine induced severe cutaneous adverse drug reaction in relation with HLA-A\*3101. Novartis. 11-Aug-2011
310. Tegretol. 2.5 Clinical Overview. Rationale for changes to Core Data Sheet (CDS) Product Information – Clinical Pharmacology and Interactions. Novartis. 11-Aug-2011

### **Newly added references - CDS update 21-Mar-2013**

311. 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Indication and dosage and administration. Novartis. 26-Feb-2013
312. 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Safety topics (Warnings and precautions, adverse drug reactions, women of child bearing potential, pregnancy, breast-feeding, overdose). Novartis. 26-Feb-2013
313. 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Clinical pharmacology and interactions. Novartis. 26-Feb-2013
314. 2.4 Nonclinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Non-clinical safety data. Novartis. 26-Feb-2013.

### Newly added references - CDS update and Amendment (bundling) 30-Jun-2017

- 315 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Safety sections- Adverse drug reactions, Warning and precautions and Interactions (Fall, cross-hypersensitivity to aromatic antiepileptic drugs, drug-drug interaction with eslicarbazepine). Novartis. 30-May-2017
- 316 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Safety sections Interaction (DDI with direct acting oral anti-coagulants). Novartis. 08-Jun-2017

### Newly added references - CDS Amendment 01-Dec-2017

- 317 2.5 Clinical Overview - Rationale for changes to Core Data Sheet (CDS)/Product Information – Section Warnings& precautions- Pregnancy and females of reproductive potential. Novartis. 10-Oct-2017

## 16 CDS history table

Vers ion	Effective date	GLC/PSB approval date	SLC Tracking No.	Section keyword	Refs.	Author(s) GLM/GPRD/G PRM
1.0	21-Mar-2013	26-Feb-2013	2013-PSB/GLC-0609-s	Changes made to following sections: <ul style="list-style-type: none"> <li>Dosage and administration</li> <li>Warnings and precautions</li> <li>Adverse drug reactions</li> <li>Women of child-bearing potential, pregnancy, breast-feeding and fertility</li> <li>Interactions</li> <li>Overdosage</li> <li>Non-clinical safety data</li> </ul>	311 312 313 314	Eric Randolph
2.0	11-Jul-2017 (Bundle d both changes)	30-May-2017	2017-PSB/GLC-0883-s (to facilitate the CDS dispatch, tracking	<b>Section 6 Warnings and precautions</b>  <b>□ Hypersensitivity</b> Cross-hypersensitivity with other aromatic antiepileptics (primidone and phenobarbital)	315	Raghuram Akinapelli
Vers ion	Effective date	GLC/PSB approval date	SLC Tracking	Section keyword No.	Refs.	Author(s) GLM/GPRD/G PRM

---

			number assigned 2017- PSB/GLC0888-s for DDIs with oral anticoagulants (was pruned)	<input type="checkbox"/> Addition of warning for "Fall" <b>Section 7 Adverse drug reactions</b> Addition of new PT Fall <b>Section 8 Interactions</b> Addition of DDI with eslicarbazepine to existing AEDs		
2.1		08-Jun- 2017		<b>Section Interactions</b> Addition of DDIs with new oral anti-coagulants (rivaroxaban, dabigatran, apixaban, edoxaban)	316	Raghuram Akinapelli
2.2	01-Dec- 2017	10-Oct- 2017	2017- PSB/GLC- 0902-s	Addition of new warning "Pregnancy and females of reproductive potential"	317	Raghuram Akinapelli

---